

# SÃ©verine Vermeire

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2366851/publications.pdf>

Version: 2024-02-01

985  
papers

86,072  
citations

381

138  
h-index

573

269  
g-index

1015  
all docs

1015  
docs citations

1015  
times ranked

55310  
citing authors

#	ARTICLE	IF	CITATIONS
1	Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 838-840.e2.	2.4	3
2	Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 85-96.	0.9	7
3	Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn's disease and is responsive to filgotinib. <i>Tissue Barriers</i> , 2023, 11, .	1.6	1
4	Collecting New Peak and Intermediate Infliximab Levels to Predict Remission in Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 208-217.	0.9	6
5	Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 689-699.	0.9	9
6	Population pharmacokineticâ€¦pharmacodynamic modelâ€¦based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 323-335.	1.1	9
7	Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 27-38.	0.6	66
8	Non-conventional Versus Conventional Strictureplasties for Crohn's Disease. A Systematic Review and Meta-analysis of Treatment Outcomes. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 319-330.	0.6	8
9	Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy. <i>Journal of Pediatrics</i> , 2022, 240, 150-157.e4.	0.9	10
10	Inflammatory Bowel Disease-related Behaviours [IBD-Bx] Questionnaire: Development, Validation and Prospective Associations with Fatigue. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 581-590.	0.6	2
11	Worldwide postâ€¦marketing safety surveillance experience with tofacitinib in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 302-310.	1.9	16
12	Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 69-95.	3.7	41
13	Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 28-37.	3.7	37
14	Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1135-1142.	0.9	5
15	Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2074-2082.	2.4	11
16	Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 171-185.	3.7	57
17	P441 Adalimumab versus ustekinumab as first-line biological in a real-life cohort of moderate-to-severe Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i423-i424.	0.6	0
18	P401 Tofacitinib tissue exposure correlates with endoscopic outcome. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i394-i395.	0.6	2

#	ARTICLE	IF	CITATIONS
19	OP03 Standardized faecal microbiota transplantation with microbiome-guided donor selection in active UC patients: A randomized, placebo-controlled intervention study. Journal of Crohn's and Colitis, 2022, 16, i003-i004.	0.6	3
20	P662 Colorectal Cancer in Patients with Ulcerative Colitis: A National Cohort Study between 1991â€“2020. Journal of Crohn's and Colitis, 2022, 16, i572-i572.	0.6	1
21	P041 Characterization of cytokine and drug concentrations in serum, mucosa and faeces during induction treatment of moderate-to-severe ulcerative colitis with anti-TNF monoclonal antibodies. Journal of Crohn's and Colitis, 2022, 16, i157-i158.	0.6	0
22	DOP90 Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn's Disease: Results from the STARDUST trial. Journal of Crohn's and Colitis, 2022, 16, i132-i134.	0.6	1
23	The Role of Carboxymethylcellulose in Health and Disease: Is the Plot Thickening?. Gastroenterology, 2022, 163, 780-781.	0.6	2
24	OP07 Exploring disease control by combining clinical, biological, and health-related quality of life remission with endoscopic improvements among Ulcerative Colitis patients treated with filgotinib: A post-hoc analysis from the SELECTION trial. Journal of Crohn's and Colitis, 2022, 16, i007-i008.	0.6	3
25	P115 Implementation of a vaccination tool in the electronic patient health record significantly increases vaccination coverage. Journal of Crohn's and Colitis, 2022, 16, i206-i207.	0.6	0
26	DOP38 Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1. Journal of Crohn's and Colitis, 2022, 16, i087-i088.	0.6	10
27	DOP41 Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative Colitis. Journal of Crohn's and Colitis, 2022, 16, i090-i091.	0.6	7
28	P004 Microbiota, not host origin drives ex vivo epithelial response in ulcerative colitis patients and non-IBD controls. Journal of Crohn's and Colitis, 2022, 16, i136-i136.	0.6	1
29	DOP89 Infliximab and ustekinumab clearance during induction predicts post-induction endoscopic outcomes in patients with Crohn's Disease. Journal of Crohn's and Colitis, 2022, 16, i131-i132.	0.6	0
30	Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises. Current Research in Pharmacology and Drug Discovery, 2022, 3, 100089.	1.7	6
31	P082 The profibrogenic role of neutrophil extracellular traps in stenotic Crohn's disease: a new antifibrotic target?. Journal of Crohn's and Colitis, 2022, 16, i182-i183.	0.6	0
32	OP34 Efficacy and safety of advanced induction and maintenance therapies in patients with moderately to severely active Ulcerative Colitis: An indirect treatment comparison using Bayesian network meta-analysis. Journal of Crohn's and Colitis, 2022, 16, i037-i041.	0.6	5
33	P533 Predictors of sustained remission after infliximab de-escalation in patients with inflammatory bowel diseases. Journal of Crohn's and Colitis, 2022, 16, i485-i486.	0.6	0
34	P073 Eosinophil depletion partially protects from colonic inflammation, but increases colonic collagen deposition in a DSS colitis model. Journal of Crohn's and Colitis, 2022, 16, i177-i178.	0.6	0
35	DOP17 Evaluating segmental healing with the modified Mayo endoscopic score (MMES) has a clear additional value in predicting long-term outcome in patients with Ulcerative Colitis: Results from a prospective cohort study. Journal of Crohn's and Colitis, 2022, 16, i066-i067.	0.6	1
36	P286 Sustained improvement in health-related quality of life outcomes in patients with Ulcerative Colitis with long-term tofacitinib treatment in the open-label extension study, OCTAVE Open. Journal of Crohn's and Colitis, 2022, 16, i317-i319.	0.6	0

#	ARTICLE	IF	CITATIONS
37	P442 Real-world endoscopic and histologic outcomes are linked to ustekinumab exposure in Ulcerative Colitis. Journal of Crohn's and Colitis, 2022, 16, i424-i424.	0.6	3
38	P475 Profiling the use of Complementary Alternative Medicines among IBD patients. Journal of Crohn's and Colitis, 2022, 16, i445-i446.	0.6	0
39	DOP81 Baseline whole-blood gene expression of TREM1 does not predict clinical or endoscopic outcomes following adalimumab treatment in patients with Ulcerative Colitis or Crohn's Disease in the SERENE studies. Journal of Crohn's and Colitis, 2022, 16, i124-i125.	0.6	3
40	P030 Distinct molecular profiles between idiopathic cryptoglandular and Crohn-related perianal fistulas. Journal of Crohn's and Colitis, 2022, 16, i151-i151.	0.6	0
41	P529 Evolution of COVID19 serology in a real-life population of IMID patients. Results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID). Journal of Crohn's and Colitis, 2022, 16, i482-i483.	0.6	0
42	OP28 A randomized placebo controlled clinical trial with 5-hydroxytryptophan in patients with quiescent Inflammatory Bowel Disease and fatigue (Trp-IBD). Journal of Crohn's and Colitis, 2022, 16, i029-i032.	0.6	0
43	DOP37 Efficacy and safety of filgotinib in patients with Ulcerative Colitis stratified by age: Post hoc analysis of the phase 2b/3 SELECTION and SELECTIONLTE studies. Journal of Crohn's and Colitis, 2022, 16, i085-i087.	0.6	2
44	DOP08 Transcriptional signatures of blood derived immune cells associated with disease location-based heterogeneity in IBD. Journal of Crohn's and Colitis, 2022, 16, i058-i058.	0.6	0
45	OP30 Upadacitinib modulates inflammatory pathways in gut tissue in patients with Ulcerative Colitis: Transcriptomic profiling from the Phase 2b study, U-ACHIEVE. Journal of Crohn's and Colitis, 2022, 16, i033-i034.	0.6	1
46	P095 Anti-inflammatory effect of high acetate concentration on organoid-derived epithelial monolayer from patients with Ulcerative Colitis. Journal of Crohn's and Colitis, 2022, 16, i192-i195.	0.6	1
47	P342 Trans-continental analysis of over, 2000 Inflammatory Bowel Disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: data from the ICARUS-IBD Consortium. Journal of Crohn's and Colitis, 2022, 16, i357-i358.	0.6	0
48	P333 Precise and unbiased infliximab dosing in patients with inflammatory bowel diseases using a multi-model averaging approach. Journal of Crohn's and Colitis, 2022, 16, i350-i351.	0.6	0
49	P576 Real-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn's disease: a Belgian multi-centric cohort study. Journal of Crohn's and Colitis, 2022, 16, i516-i517.	0.6	2
50	P517 Re-treatment with filgotinib in patients with Ulcerative Colitis following treatment interruption: Analysis of the SELECTION and SELECTIONLTE studies. Journal of Crohn's and Colitis, 2022, 16, i473-i474.	0.6	2
51	P370 Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from, 52-week phase, 3 study U ACHIEVE maintenance. Journal of Crohn's and Colitis, 2022, 16, i373-i374.	0.6	2
52	P447 Positioning of ustekinumab affects its effectiveness, drug persistence and serum exposure in Crohn's disease. Journal of Crohn's and Colitis, 2022, 16, i427-i428.	0.6	0
53	N01 Type of patient education impacts the willingness to switch from an IV to SC of a biological in patients with Inflammatory Bowel Disease: A multicentre, comparative study. Journal of Crohn's and Colitis, 2022, 16, i617-i618.	0.6	1
54	OP19 Classifying perianal fistulising Crohn's Disease: An expert-consensus to guide decision-making in daily practice and clinical trials. Journal of Crohn's and Colitis, 2022, 16, i021-i022.	0.6	1

#	ARTICLE	IF	CITATIONS
55	P257 The clinical decision support tool has low performance in predicting outcome to ustekinumab in Crohn's disease. Journal of Crohn's and Colitis, 2022, 16, i298-i299.	0.6	0
56	Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. The Lancet Gastroenterology and Hepatology, 2022, 7, 294-306.	3.7	42
57	Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All. Journal of Crohn's and Colitis, 2022, 16, 1306-1320.	0.6	11
58	Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 351-366.	8.2	43
59	Integrated analysis of microbe-host interactions in Crohn's disease reveals potential mechanisms of microbial proteins on host gene expression. IScience, 2022, 25, 103963.	1.9	7
60	Postoperative Crohn's Disease Recurrence: Time to Adapt Endoscopic Recurrence Scores to the Leading Surgical Techniques. Clinical Gastroenterology and Hepatology, 2022, 20, 1201-1204.	2.4	13
61	Proctocolectomy and ileal pouch-anal anastomosis for the treatment of collagenous colitis. Clinical Journal of Gastroenterology, 2022, , 1.	0.4	2
62	Classifying perianal fistulising Crohn's disease: an expert consensus to guide decision-making in daily practice and clinical trials. The Lancet Gastroenterology and Hepatology, 2022, 7, 576-584.	3.7	17
63	Next generation point-of-care test for therapeutic drug monitoring of adalimumab in patients diagnosed with autoimmune diseases. Biosensors and Bioelectronics, 2022, 208, 114189.	5.3	17
64	Safety of sequential biological therapy in inflammatory bowel disease: results from a tertiary referral Centre. Alimentary Pharmacology and Therapeutics, 2022, , .	1.9	1
65	Longitudinal monitoring of <sc>STAT3</sc> phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2022, 56, 282-291.	1.9	5
66	A systems genomics approach to uncover patient-specific pathogenic pathways and proteins in ulcerative colitis. Nature Communications, 2022, 13, 2299.	5.8	9
67	Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: <sc>ERELATE</sc> Study. Alimentary Pharmacology and Therapeutics, 2022, 56, 463-476.	1.9	12
68	Closing the gender gap: building a successful career and leadership in research as a female gastroenterologist. The Lancet Gastroenterology and Hepatology, 2022, 7, 501-502.	3.7	3
69	Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 1045-1059.	1.3	9
70	Microbiota, not host origin drives <i>ex vivo</i> intestinal epithelial responses. Gut Microbes, 2022, 14, .	4.3	8
71	Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab Concentrations. Journal of Crohn's and Colitis, 2021, 15, 988-993.	0.6	7
72	Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial. Journal of Crohn's and Colitis, 2021, 15, 1130-1141.	0.6	37

#	ARTICLE	IF	CITATIONS
73	High-Dose Vitamin D Does Not Prevent Postoperative Recurrence of Crohn's Disease in a Randomized Placebo-Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1573-1582.e5.	2.4	20
74	Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 106-118.	1.1	18
75	Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 947-954.e2.	2.4	15
76	Variability in the Distribution of Histological Disease Activity in the Colon of Patients with Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 603-608.	0.6	6
77	Rates of Postoperative Recurrence of Crohn's Disease and Effects of Immunosuppressive and Biologic Therapies. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 713-720.e1.	2.4	31
78	Computer-Aided Diagnosis With Monochromatic Light Endoscopy for Scoring Histologic Remission in Ulcerative Colitis. <i>Gastroenterology</i> , 2021, 160, 23-25.	0.6	16
79	Thiopurine monotherapy has a limited place in treatment of patients with mild-to-moderate Crohn's disease. <i>Gut</i> , 2021, 70, 1416-1418.	6.1	9
80	Intestinal Receptor of SARS-CoV-2 in Inflamed IBD Tissue Seems Downregulated by HNF4A in Ileum and Upregulated by Interferon Regulating Factors in Colon. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 485-498.	0.6	34
81	Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 950-959.	0.6	42
82	PPIs and anti-TNF in patients with IBD: a forbidden combination?. <i>Gut</i> , 2021, 70, 2397.1-2398.	6.1	0
83	Positioning strictureplasty in the treatment of extensive Crohn's disease ileitis: a comparative study with ileocecal resection. <i>International Journal of Colorectal Disease</i> , 2021, 36, 791-799.	1.0	5
84	P117...Filgotinib reduces markers of JAK1 signaling in Crohn's disease: concordance with endoscopy and histopathology. , 2021, , .		0
85	Health Literacy and Quality of Life in Young Adults From The Belgian Crohn's Disease Registry Compared to Type 1 Diabetes Mellitus. <i>Frontiers in Pediatrics</i> , 2021, 9, 624416.	0.9	5
86	Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 938-949.	0.6	23
87	Effect of vedolizumab dose intensification on serum drug concentrations and regain of response in inflammatory bowel disease patients with secondary loss of response. <i>GastroHep</i> , 2021, 3, 63-71.	0.3	8
88	Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1564-1575.	0.9	53
89	Monocyte TREM-1 Levels Associate With Anti-TNF Responsiveness in IBD Through Autophagy and FcÎ³-Receptor Signaling Pathways. <i>Frontiers in Immunology</i> , 2021, 12, 627535.	2.2	13
90	NOD2 drives early IL-33-dependent expansion of group 2 innate lymphoid cells during Crohn's disease-like ileitis. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	28



#	ARTICLE	IF	CITATIONS
91	The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases. British Journal of Clinical Pharmacology, 2021, 87, 3776-3789.	1.1	8
92	Let Food Be Thy Medicineâ€™s Role in Crohnâ€™s Disease. Nutrients, 2021, 13, 832.	1.7	6
93	Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials. Journal of Crohn's and Colitis, 2021, 15, 1852-1863.	0.6	16
94	Short chain fatty acids and its producing organisms: An overlooked therapy for IBD?. EBioMedicine, 2021, 66, 103293.	2.7	281
95	Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD. Gastroenterology, 2021, 160, 1452-1460.e21.	0.6	68
96	Fungal and Bacterial Loads: Noninvasive Inflammatory Bowel Disease Biomarkers for the Clinical Setting. MSystems, 2021, 6, .	1.7	15
97	P440 First results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID). Journal of Crohn's and Colitis, 2021, 15, S440-S440.	0.6	1
98	DOP82 Corticosteroid-free remission of Ulcerative Colitis with filgotinib maintenance therapy: Post hoc analysis of the phase 2b/3 SELECTION study. Journal of Crohn's and Colitis, 2021, 15, S112-S113.	0.6	0
99	P062 Effects of exposure to steroids on the PredictSURE whole blood prognostic assay in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, S168-S168.	0.6	4
100	P354 Early treatment versus active surveillance after ileocolic resection in Crohnâ€™s disease: a retrospective cohort study. Journal of Crohn's and Colitis, 2021, 15, S373-S374.	0.6	0
101	OP24 Efficacy and safety of upadacitinib induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from the phase 3 U-ACHIEVE study. Journal of Crohn's and Colitis, 2021, 15, S022-S024.	0.6	13
102	DOP22 Integrative -omic analysis reveals microbiota mediated molecular mechanisms influencing host mucosal gene expression in Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2021, 15, S061-S062.	0.6	0
103	P063 The immunological landscape of intestinal fibrosis in Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2021, 15, S168-S169.	0.6	0
104	OP40 Analysis of clinical features associated with favourable outcomes from ustekinumab treat-to-target strategy in Crohnâ€™s Disease patients in the STARDUST trial. Journal of Crohn's and Colitis, 2021, 15, S039-S039.	0.6	1
105	OP14 Extracellular RNAs as liquid biopsy non-invasive biomarker in IBD. Journal of Crohn's and Colitis, 2021, 15, S014-S015.	0.6	0
106	P497 The value of endoscopic healing index monitoring for guiding infliximab dosing in patients with Crohnâ€™s disease. Journal of Crohn's and Colitis, 2021, 15, S481-S483.	0.6	0
107	P095 Initial disease course in a Belgian, prospective inception cohort of patients with inflammatory bowel disease: the PANTHER cohort. Journal of Crohn's and Colitis, 2021, 15, S192-S193.	0.6	0
108	OP23 Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study. Journal of Crohn's and Colitis, 2021, 15, S021-S022.	0.6	17

#	ARTICLE	IF	CITATIONS
109	P484 Remote monitoring allows an individualized approach and showed excellent usability at the infusion unit. Journal of Crohn's and Colitis, 2021, 15, S472-S473.	0.6	0
110	Computational Biology and Machine Learning Approaches to Understand Mechanistic Microbiome-Host Interactions. Frontiers in Microbiology, 2021, 12, 618856.	1.5	19
111	P304 Rational infliximab induction dosing to achieve long-term deep remission in children with Inflammatory Bowel Diseases. Journal of Crohn's and Colitis, 2021, 15, S332-S333.	0.6	0
112	P405 Development and validation of a rapid immunoassay for monitoring of ustekinumab concentrations in Inflammatory Bowel Disease patients. Journal of Crohn's and Colitis, 2021, 15, S412-S412.	0.6	0
113	DOP84 Early treatment responses within 14 days of intravenous vedolizumab induction therapy for Crohn's Disease: Post hoc analysis of patient-reported outcomes from the VISIBLE 2 study. Journal of Crohn's and Colitis, 2021, 15, S115-S116.	0.6	0
114	DOP61 Impact of prior tumour necrosis factor inhibitor failure and prior corticosteroid use on the maintenance of efficacy of tofacitinib following dose reduction in patients with Ulcerative Colitis who were in stable remission: 6-month data from the double-blind, randomised RIVETING study. Journal of Crohn's and Colitis, 2021, 15, S096-S097.	0.6	0
115	P676 The small intestinal microbiome in Crohn's disease is characterised by increased luminal diversity and stable mucosa-associated communities. Journal of Crohn's and Colitis, 2021, 15, S597-S598.	0.6	0
116	P361 No increased postoperative risk of venous thromboembolism in patients with Ulcerative Colitis undergoing colectomy after tofacitinib exposure. Journal of Crohn's and Colitis, 2021, 15, S380-S380.	0.6	0
117	P309 Are results from VARSITY applicable to real world? Adalimumab versus vedolizumab as first line biological in moderate-to-severe IBD. Journal of Crohn's and Colitis, 2021, 15, S336-S337.	0.6	0
118	DOP08 Serum proteomics predict endoscopic remission in patients with Crohn's Disease. Journal of Crohn's and Colitis, 2021, 15, S046-S047.	0.6	0
119	P527 Investigating fatigue in vedolizumab-treated patients with ulcerative colitis or Crohn's disease from a Belgian registry. Journal of Crohn's and Colitis, 2021, 15, S503-S503.	0.6	0
120	P579 Online Education Significantly Improved Gastroenterologists' Knowledge of Treatment Options and Therapeutic Goals in Ulcerative Colitis. Journal of Crohn's and Colitis, 2021, 15, S534-S535.	0.6	0
121	P465 One year endoscopic and histologic outcomes to tofacitinib therapy in refractory ulcerative colitis. Journal of Crohn's and Colitis, 2021, 15, S456-S457.	0.6	0
122	OP35 Effect of maintenance ustekinumab on corticosteroid-free endoscopic and clinical outcomes in patients with Crohn's Disease - Week 48 analysis of the STARDUST trial. Journal of Crohn's and Colitis, 2021, 15, S032-S033.	0.6	1
123	P301 Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: results up to Week 48 of the STARDUST trial. Journal of Crohn's and Colitis, 2021, 15, S330-S331.	0.6	2
124	P082 Assessment of anti-inflammatory effect of high acetate administration in UC patient-derived epithelial monolayer cultures. Journal of Crohn's and Colitis, 2021, 15, S182-S183.	0.6	0
125	P307 Modelling of the relationship between ustekinumab exposure, faecal calprotectin and endoscopic outcomes in patients with Crohn's disease. Journal of Crohn's and Colitis, 2021, 15, S335-S336.	0.6	0
126	P027 Epithelial cells of patients with ulcerative colitis do not show an increased sensitivity after microbiota stimulation compared to non-IBD controls. Journal of Crohn's and Colitis, 2021, 15, S142-S143.	0.6	0



#	ARTICLE	IF	CITATIONS
127	DOP07 Ulcerative Colitis associated single nucleotide polymorphisms found in transcription factor binding sites effect key pathogenesis pathways and facilitate patient stratification. Journal of Crohn's and Colitis, 2021, 15, S045-S046.	0.6	0
128	P311 Intensive dried blood spot sampling shows a higher drug exposure throughout the first 24 weeks of therapy in ustekinumab-treated Crohn's disease patients achieving endoscopic remission. Journal of Crohn's and Colitis, 2021, 15, S338-S339.	0.6	0
129	Therapeutic outcome of diverticular associated colitis â€” a retrospective single centre experience. Acta Gastro-Enterologica Belgica, 2021, 84, 275-281.	0.4	5
130	Induction and Long-term Follow-up With ABX464 for Moderate-to-severe Ulcerative Colitis: Results of Phase IIa Trial. Gastroenterology, 2021, 160, 2595-2598.e3.	0.6	32
131	Breaking the therapeutic ceiling in drug development in ulcerative colitis. The Lancet Gastroenterology and Hepatology, 2021, 6, 589-595.	3.7	65
132	The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey. Lancet Regional Health - Europe, The, 2021, 9, 100181.	3.0	43
133	Long-term clinical outcome after thiopurine discontinuation in elderly IBD patients. Scandinavian Journal of Gastroenterology, 2021, 56, 1323-1327.	0.6	2
134	Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium. The Lancet Gastroenterology and Hepatology, 2021, 6, 826-849.	3.7	69
135	Venous thrombotic events in psoriasis patients: a systematic review with meta-analysis. Annals of Medicine, 2021, 53, 1076-1083.	1.5	9
136	Understanding the Molecular Drivers of Disease Heterogeneity in Crohn's Disease Using Multi-omic Data Integration and Network Analysis. Inflammatory Bowel Diseases, 2021, 27, 870-886.	0.9	24
137	Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX. American Journal of Gastroenterology, 2021, 116, 134-141.	0.2	11
138	Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis. Pharmaceutics, 2021, 13, 1623.	2.0	4
139	Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials. Alimentary Pharmacology and Therapeutics, 2021, 54, 1442-1453.	1.9	4
140	Role of Eosinophils in Intestinal Inflammation and Fibrosis in Inflammatory Bowel Disease: An Overlooked Villain?. Frontiers in Immunology, 2021, 12, 754413.	2.2	24
141	PMO-30â€¦Corticosteroid-free remission of ulcerative colitis with filgotinib maintenance therapy: post-hoc analysis of the SELECTION study. , 2021, , .		0
142	Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme. Alimentary Pharmacology and Therapeutics, 2021, 53, 265-272.	1.9	3
143	Temporal variability in quantitative human gut microbiome profiles and implications for clinical research. Nature Communications, 2021, 12, 6740.	5.8	89
144	Dysbiosis and relapse-related microbiome in inflammatory bowel disease: A shotgun metagenomic approach. Computational and Structural Biotechnology Journal, 2021, 19, 6481-6489.	1.9	21

#	ARTICLE	IF	CITATIONS
145	Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 265-272.	1.9	13
146	Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 628-634.	0.9	9
147	Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2139-2141.e2.	2.4	17
148	Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2020, 158, 562-572.e12.	0.6	173
149	Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1142-1151.e10.	2.4	50
150	Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling. <i>Gut</i> , 2020, 69, 1053-1063.	6.1	109
151	How, When, and for Whom Should We Perform Therapeutic Drug Monitoring?. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1291-1299.	2.4	62
152	Protein Glycosylation as a Diagnostic and Prognostic Marker of Chronic Inflammatory Gastrointestinal and Liver Diseases. <i>Gastroenterology</i> , 2020, 158, 95-110.	0.6	95
153	Long-term outcome of immunomodulator use in pediatric patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2020, 52, 164-172.	0.4	11
154	Risk of Development of More-advanced Lesions in Patients With Inflammatory Bowel Diseases and Dysplasia. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1528-1536.e5.	2.4	29
155	Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 332-341.	0.6	27
156	Osteonecrosis of the jaw in patients with inflammatory bowel disease treated with tumour necrosis factor alpha inhibitors. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2020, 49, 317-324.	0.7	14
157	Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins. <i>Gastroenterology</i> , 2020, 158, 515-526.e10.	0.6	65
158	Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 637-646.e11.	2.4	67
159	The Ulcerative Colitis Response Index for Detection of Mucosal Healing in Patients Treated With Anti-tumour Necrosis Factor. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 176-184.	0.6	7
160	Mucosal microbial load in Crohn's disease: A potential predictor of response to faecal microbiota transplantation. <i>EBioMedicine</i> , 2020, 51, 102611.	2.7	21
161	Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density. <i>Gut</i> , 2020, 69, 1778-1786.	6.1	79
162	Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1704-1718.	2.4	19

#	ARTICLE	IF	CITATIONS
163	Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2020, 158, 550-561.	0.6	144
164	Successful Infliximab Treatment is Associated With Reversal of Clotting Abnormalities in Inflammatory Bowel Disease Patients. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 819-825.	1.1	9
165	Betting on quality indicators to improve inflammatory bowel disease surveillance outcome: All in or one to pick?. <i>Digestive Endoscopy</i> , 2020, 32, 523-525.	1.3	1
166	Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 435-445.	1.9	26
167	Review article: how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1453-1468.	1.9	36
168	Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?. <i>Current Opinion in Pharmacology</i> , 2020, 55, 17-30.	1.7	23
169	P219 Disease-specific avoidance is a predictor for fatigue in inflammatory bowel disease patients. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S250-S252.	0.6	0
170	P341 Induction of response and remission: a network meta-analysis of induction studies comparing ontamalimab with other treatments for moderate-to-severe ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S327-S328.	0.6	0
171	P362 Prospective study of phArmaCokinetics of InFliximab during induction in patients with Crohn's disease and ulcerative colitis (PACIFIC). <i>Journal of Crohn's and Colitis</i> , 2020, 14, S343-S344.	0.6	0
172	P389 Post induction infliximab trough levels predict long-term endoscopic remission in paediatric patients with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S362-S363.	0.6	0
173	P391 Side-to-side strictureplasty and its modification over the ileocecal valve for extensive Crohn's ileitis: single-centre long-term outcome. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S365-S366.	0.6	0
174	P418 Filgotinib decreases molecular markers of JAK1 signal transduction in Crohn's disease: concordance with endoscopy and histopathology. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S381-S381.	0.6	0
175	P421 Prognostic and therapeutic long-term outcome of patients with ulcerative proctitis: analysis from a large referral centre cohort study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S383-S384.	0.6	0
176	P463 Induction of endoscopic response: a network meta-analysis of induction studies comparing ontamalimab with other treatments for moderate-to-severe ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S410-S411.	0.6	0
177	P464 Vedolizumab concentrations in colonic mucosal tissue of ulcerative colitis patients inversely correlate with the severity of inflammation. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S411-S412.	0.6	1
178	P539 Assessment of age as a risk factor for adverse events in patients from the tofacitinib ulcerative colitis clinical programme. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S460-S461.	0.6	0
179	P603 Persistence of vedolizumab maintenance therapy: Findings from a Belgian registry. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S503-S504.	0.6	0
180	Biological Therapy in Inflammatory Bowel Disease Patients Partly Restores Intestinal Innate Lymphoid Cell Subtype Equilibrium. <i>Frontiers in Immunology</i> , 2020, 11, 1847.	2.2	25

#	ARTICLE	IF	CITATIONS
181	2020 international consensus on ANCA testing beyond systemic vasculitis. <i>Autoimmunity Reviews</i> , 2020, 19, 102618.	2.5	79
182	Worries and concerns of inflammatory bowel disease (IBD) patients in Belgium â€” a validation of the Dutch rating form. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 1427-1432.	0.6	3
183	Molecular Changes in the Non-Inflamed Terminal Ileum of Patients with Ulcerative Colitis. <i>Cells</i> , 2020, 9, 1793.	1.8	4
184	JAK Inhibitors: Back to Small Molecules for the Treatment of IBD. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S711-S712.	0.6	4
185	P542 The effect of age on infliximab pharmacokinetics in patients with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S462-S463.	0.6	0
186	Long-term safety of vedolizumab for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1353-1365.	1.9	97
187	Invasive nocardiosis, disseminated varicella zoster reactivation, and pneumocystis jiroveci pneumonia associated with tofacitinib and concomitant systemic corticosteroid use in ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2294-2297.	1.4	8
188	Assessing Disease Activity in Ulcerative Colitis Using Artificial Intelligence: Can â€œEqually Goodâ€• Be Seen as â€œBetterâ€•? <i>Gastroenterology</i> , 2020, 159, 1625-1626.	0.6	10
189	Thiopurines in Pediatric Inflammatory Bowel Disease: Current and Future Place. <i>Paediatric Drugs</i> , 2020, 22, 449-461.	1.3	2
190	Genetic Variants of the MGAT5 Gene Are Functionally Implicated in the Modulation of T Cells Glycosylation and Plasma IgG Glycome Composition in Ulcerative Colitis. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00166.	1.3	20
191	Etolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program. <i>Advances in Therapy</i> , 2020, 37, 3417-3431.	1.3	64
192	Ex Vivo Mimicking of Inflammation in Organoids Derived From Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2020, 159, 1564-1567.	0.6	36
193	Fibrogenesis in chronic murine colitis is independent of innate lymphoid cells. <i>Immunity, Inflammation and Disease</i> , 2020, 8, 393-407.	1.3	4
194	Neutrophilic HGF-MET Signalling Exacerbates Intestinal Inflammation. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1748-1758.	0.6	12
195	Development and feasibility of a telemonitoring tool with full integration in the electronic medical record: a proof of concept study for patients with inflammatory bowel disease in remission on biological therapy. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 287-293.	0.6	7
196	JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 323-337.	8.2	336
197	Evaluating an easy sampling method using dried blood spots to determine vedolizumab concentrations. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 185, 113224.	1.4	12
198	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2632-2633.	2.4	0

#	ARTICLE	IF	CITATIONS
199	OP20 The gut microbiota during biological therapy for inflammatory bowel disease. Journal of Crohn's and Colitis, 2020, 14, S016-S018.	0.6	0
200	P061 The molecular landscape of perianal fistula in Crohn's disease: opportunities for new therapeutic approaches. Journal of Crohn's and Colitis, 2020, 14, S165-S165.	0.6	3
201	Long-term outcomes of patients with ulcerative proctitis: Analysis from a large referral centre cohort. United European Gastroenterology Journal, 2020, 8, 933-941.	1.6	18
202	DOP13 Clinical and endoscopic response to ustekinumab in Crohn's disease: Week 16 interim analysis of the STARDUST trial. Journal of Crohn's and Colitis, 2020, 14, S049-S052.	0.6	4
203	DOP81 Time to loss of efficacy among patients in remission following induction treatment with tofacitinib 10 mg BID who reduced tofacitinib dose or discontinued tofacitinib in OCTAVE sustain. Journal of Crohn's and Colitis, 2020, 14, S120-S121.	0.6	0
204	Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis. Journal of Crohn's and Colitis, 2020, 14, 1066-1073.	0.6	16
205	Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2020, 18, 2295-2304.e2.	2.4	18
206	P601 Development and validation of dried blood spot sampling as a tool to identify the best time point to measure predictive ustekinumab serum concentrations in patients with Crohn's disease. Journal of Crohn's and Colitis, 2020, 14, S502-S502.	0.6	2
207	P269 Mucosal capillary pattern recognition based on real-time computer-aided image analysis adequately detects histological remission in ulcerative colitis. Journal of Crohn's and Colitis, 2020, 14, S284-S285.	0.6	1
208	DOP14 Modelling of the relationship between infliximab exposure, faecal calprotectin, and endoscopic remission in patients with Crohn's disease. Journal of Crohn's and Colitis, 2020, 14, S052-S053.	0.6	3
209	Does mucosal inflammation drive recurrence of primary sclerosing cholangitis in liver transplantation recipients with ulcerative colitis?. Digestive and Liver Disease, 2020, 52, 528-533.	0.4	3
210	OP37 Fibrogenesis in chronic DSS colitis is driven by an innate lymphoid cell-independent innate immune response. Journal of Crohn's and Colitis, 2020, 14, S038-S039.	0.6	0
211	DOP16 An evaluation of the exposure-efficacy relationship for subcutaneous vedolizumab maintenance treatment of Crohn's disease: Pharmacokinetic findings from VISIBLE 2. Journal of Crohn's and Colitis, 2020, 14, S056-S057.	0.6	1
212	DOP60 Vedolizumab treatment persistence and safety in an extended access program (XAP). Journal of Crohn's and Colitis, 2020, 14, S099-S100.	0.6	0
213	Big data in IBD: big progress for clinical practice. Gut, 2020, 69, 1520-1532.	6.1	121
214	Short- and Long-term Outcomes Following Side-to-side Strictureplasty and its Modification Over the Ileocaecal Valve for Extensive Crohn's Ileitis. Journal of Crohn's and Colitis, 2020, 14, 1378-1384.	0.6	8
215	Early Postoperative Endoscopic Recurrence in Crohn's Disease Is Characterised by Distinct Microbiota Recolonisation. Journal of Crohn's and Colitis, 2020, 14, 1535-1546.	0.6	38
216	DOP31 Serum protein markers for early and differential IBD diagnosis validated by machine learning approaches. Journal of Crohn's and Colitis, 2020, 14, S070-S070.	0.6	0

#	ARTICLE	IF	CITATIONS
217	DOP37 Neoplastic lesions outside diseased area in inflammatory bowel disease patients: A national cohort study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S074-S075.	0.6	0
218	P399 Endoscopic and histologic outcome in tofacitinib treated refractory moderate-to-severe ulcerative colitis: A prospective real-life cohort. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S369-S370.	0.6	3
219	MUCOSAL CAPILLARY PATTERN RECOGNITION WITH REAL-TIME COMPUTER-BASED IMAGE ANALYSIS DETECTS HISTOLOGICAL REMISSION IN ULCERATIVE COLITIS. , 2020, , .		0
220	AB0511â€¦INTERNATIONAL CONSENSUS ON ANCA TESTING AND INTERPRETATION BEYOND SYSTEMIC VASCULITIS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1553.2-1553.	0.5	0
221	NMI and IFP35 are key DAMP molecules in inflammatory bowel diseases. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
222	Quality of care in an inflammatory bowel disease clinical trial center : a prospective study evaluating patients' satisfaction. <i>Acta Gastro-Enterologica Belgica</i> , 2020, 83, 25-31.	0.4	1
223	Mesenteric panniculitis as a presentation of Whipple's disease: case report and review of the literature. <i>Acta Gastro-Enterologica Belgica</i> , 2020, 83, 666-668.	0.4	1
224	Membranous colitis: a potentially bone-deep diagnosis. <i>Acta Gastro-Enterologica Belgica</i> , 2020, 83, 674.	0.4	0
225	TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn's disease patients?. <i>Gut</i> , 2019, 68, 1531-1533.	6.1	42
226	A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2019, 26, 570-580.	0.9	10
227	Fibrogenesis in Chronic DSS Colitis is Not Influenced by Neutralisation of Regulatory T Cells, of Major T Helper Cytokines or Absence of IL-13. <i>Scientific Reports</i> , 2019, 9, 10064.	1.6	10
228	P435 Rapidity of symptomatic and inflammatory biomarker improvements following upadacitinib induction treatment: data from the U-ACHIEVE study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S326-S327.	0.6	1
229	P032 Hepatocyte growth factor and MET in ulcerative colitis, novel drug targets impairing neutrophil recruitment?. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S102-S102.	0.6	0
230	Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD). <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 943-954.	1.5	40
231	P374 Effects of subcutaneous vedolizumab on health-related quality of life and work productivity in patients with ulcerative colitis: results from the Phase 3 VISIBLE 1 trial. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S292-S292.	0.6	3
232	P131 Effectiveness and safety of vedolizumab maintenance therapy for inflammatory bowel disease: findings from a Belgian registry. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S153-S154.	0.6	0
233	DOP26 Biological therapy increases NCR+ ILC3 levels in IBD patients. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S040-S040.	0.6	2
234	Inflammatory Bowel Disease (IBD)â€”A Textbook Case for Multi-Centric Banking of Human Biological Materials. <i>Frontiers in Medicine</i> , 2019, 6, 230.	1.2	3



#	ARTICLE	IF	CITATIONS
235	Expert consensus: practical algorithms for management of inflammatory bowel disease patients presenting with back pain or peripheral arthropathies. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1204-1213.	1.9	11
236	Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2019, 157, 997-1006.e6.	0.6	86
237	Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. <i>Gastroenterology</i> , 2019, 157, 1007-1018.e7.	0.6	145
238	OP09 Histological remission and mucosal healing in a randomised, placebo-controlled, Phase 2 study of etrasimod in patients with moderately to severely active ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S006-S006.	0.6	7
239	OP11 Organoids derived from inflamed intestinal biopsies of patients with ulcerative colitis lose their inflammatory phenotype during <i>ex vivo</i> culture. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S007-S007.	0.6	2
240	OP21 ABX464 is safe and efficacious in a proof-of-concept study in ulcerative colitis patients. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S014-S015.	0.6	11
241	OP25 Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S016-S018.	0.6	1
242	OP26 Long-term safety of vedolizumab in ulcerative colitis and Crohn's disease: final results from the GEMINI LTS study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S018-S020.	0.6	8
243	OP30 Serum proteomic profiling predicts and diagnoses pouchitis in ulcerative colitis patients undergoing ileal pouch-anal anastomosis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S022-S023.	0.6	0
244	DOP29 Pregnancy outcomes in IBD patients treated with vedolizumab, anti-TNF, or conventional therapy. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S041-S042.	0.6	4
245	DOP33 Long-term clinical efficacy of ustekinumab in refractory Crohn's disease : a multi-centre Belgian cohort study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S044-S045.	0.6	1
246	DOP37 Vedolizumab-induced endoscopic remission in anti-TNF exposed and anti-TNF naïve IBD patients: a large single-centre experience. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S047-S048.	0.6	1
247	DOP38 A vedolizumab specific four-gene colonic signature accurately predicting future endoscopic remission in patients with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S048-S048.	0.6	1
248	DOP49 Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in ulcerative colitis: results from the open-label extension study TURANDOT II. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S056-S057.	0.6	4
249	DOP51 Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S058-S059.	0.6	2
250	Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease. <i>EBioMedicine</i> , 2019, 40, 733-742.	2.7	119
251	OP10 Systems genomics of ulcerative colitis: combining GWAS and signalling networks for patient stratification and individualised drug targeting in ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S006-S007.	0.6	0
252	DOP70 An integrated multi-omics biomarker predicting endoscopic response in ustekinumab treated patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S072-S073.	0.6	9

#	ARTICLE	IF	CITATIONS
253	P342 A population pharmacokinetic model to support therapeutic drug monitoring during vedolizumab therapy. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S273-S274.	0.6	4
254	Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 864-872.	0.6	83
255	Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 572-581.	1.9	52
256	Quantitative microbiome profiling disentangles inflammation- and bile duct obstruction-associated microbiota alterations across PSC/IBD diagnoses. <i>Nature Microbiology</i> , 2019, 4, 1826-1831.	5.9	149
257	Cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn's disease. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 607-616.	1.4	14
258	New biologics and small molecules in inflammatory bowel disease: an update. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481985320.	1.4	82
259	Short Health Scale: a valid and reliable measure of quality of life in Dutch speaking patients with inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 592-596.	0.6	3
260	Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview. <i>BMC Medicine</i> , 2019, 17, 89.	2.3	40
261	P821 Distinct and common gene expression profiles between inflamed ileum and colon of newly diagnosed CD patients. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S533-S533.	0.6	0
262	P253 The impact of storage time and freeze-thaw cycles on faecal calprotectin concentration in inflammatory bowel disease patients and controls. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S223-S223.	0.6	0
263	P542 Efficacy and safety of biological therapies in chronic antibiotic-refractory pouchitis: a retrospective single-centre experience. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S385-S385.	0.6	1
264	Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1401-1409.	0.6	92
265	Investing in workability of patients with inflammatory bowel disease: results of a pilot project Activ84work (Activate for work). <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 94-98.	0.8	2
266	The human microbiome in health and disease: hype or hope. <i>Acta Clinica Belgica</i> , 2019, 74, 53-64.	0.5	34
267	Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1248-1256.	0.6	32
268	Butyrate Does Not Protect Against Inflammation-induced Loss of Epithelial Barrier Function and Cytokine Production in Primary Cell Monolayers From Patients With Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1351-1361.	0.6	48
269	P687 Clinical remission demonstrated with oral ozanimod in the overall population and across multiple subgroups of patients with moderately to severely active ulcerative colitis in the TOUCHSTONE trial. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S464-S464.	0.6	2
270	P011 Signalling and transcriptional network propagation uncovers novel ulcerative colitis pathogenetic pathways from single-nucleotide polymorphisms. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S091-S092.	0.6	0

#	ARTICLE	IF	CITATIONS
271	P478 Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients. Journal of Crohn's and Colitis, 2019, 13, S351-S351.	0.6	0
272	P827 Up-regulation of IL17-related pathways in affected colon from ulcerative colitis compared with Crohn's disease. Journal of Crohn's and Colitis, 2019, 13, S537-S538.	0.6	0
273	P112 Long-term outcome of immunomodulators use in paediatric patients with inflammatory bowel disease. Journal of Crohn's and Colitis, 2019, 13, S143-S144.	0.6	0
274	P589 A population pharmacokinetic model to improve mucosal healing upon golimumab induction therapy in patients with ulcerative colitis. Journal of Crohn's and Colitis, 2019, 13, S409-S410.	0.6	1
275	P699 Faecal microbiota transplantation as treatment for recurrent clostridium difficile infections: a single-centre experience. Journal of Crohn's and Colitis, 2019, 13, S470-S470.	0.6	0
276	Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases. United European Gastroenterology Journal, 2019, 7, 750-758.	1.6	10
277	Editorial: biomarker predictors of non-response to <sc>TNF</sc> antagonists " the quest continues. Authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 49, 1091-1092.	1.9	0
278	Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus. Digestive Diseases, 2019, 37, 266-283.	0.8	63
279	Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials. Journal of Crohn's and Colitis, 2019, 13, 1227-1233.	0.6	7
280	P499 Efficacy and safety of 2 or 3 vedolizumab intravenous infusions as induction therapy for ulcerative colitis and Crohn's disease: results from VISIBLE 1 and 2. Journal of Crohn's and Colitis, 2019, 13, S361-S362.	0.6	0
281	P408 Switching from infliximab originator to a biosimilar does not affect efficacy, pharmacokinetics and immunogenicity in paediatric patients with inflammatory bowel disease. Journal of Crohn's and Colitis, 2019, 13, S313-S314.	0.6	0
282	P385 TREM1, the first anti-TNF specific biomarker guiding therapeutic decision. Journal of Crohn's and Colitis, 2019, 13, S300-S300.	0.6	0
283	P836 The predictive role of gut microbiota in treatment response to vedolizumab and ustekinumab in inflammatory bowel disease. Journal of Crohn's and Colitis, 2019, 13, S542-S542.	0.6	1
284	Efficacy and Safety of Abirumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis. Gastroenterology, 2019, 156, 946-957.e18.	0.6	66
285	OTH-12...Efficacy and safety of vedolizumab subcutaneous formulation for ulcerative colitis: results of the visible trial. , 2019, , ,		1
286	P454 Prediction of endoscopic activity in patients with Crohn's disease: systematic review and external validation of published prediction models. Journal of Crohn's and Colitis, 2019, 13, S338-S339.	0.6	0
287	P265 Pharmacokinetic and pharmacodynamic evaluation of radiological healing in Crohn's disease patients treated with Infliximab: a TAILORIX MRE substudy. Journal of Crohn's and Colitis, 2019, 13, S231-S231.	0.6	1
288	P290 Compliance to vaccination guidelines in patients with immune-mediated inflammatory diseases: a cross-sectional, single-centre study. Journal of Crohn's and Colitis, 2019, 13, S244-S245.	0.6	0

#	ARTICLE	IF	CITATIONS
289	Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease. Therapeutic Drug Monitoring, 2019, 41, 317-324.	1.0	26
290	P194 Automated real-time endoscopic scoring based on machine learning in ulcerative colitis: Red Density reliability and responsiveness study. Journal of Crohn's and Colitis, 2019, 13, S187-S188.	0.6	0
291	Outcome of biological therapies in chronic antibioticâ€refractory pouchitis: A retrospective singleâ€centre experience. United European Gastroenterology Journal, 2019, 7, 1215-1225.	1.6	32
292	Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2019, 68, 847-853.	0.9	36
293	772â€Long-Term Mucosal Healing, Clinical Response and Clinical Remission in Patients With Ulcerative Colitis Treated With the Anti-MAdCAM-1 Antibody Ontamalimab: Results From the Open-Label Extension Study TURANDOT II. American Journal of Gastroenterology, 2019, 114, S448-S449.	0.2	1
294	764â€Long-Term Efficacy and Safety of Etrasimod for Ulcerative Colitis: Results From the Open-Label Extension of the OASIS Study. American Journal of Gastroenterology, 2019, 114, S445-S446.	0.2	0
295	Immunogenicity is not the driving force of treatment failure in vedolizumabâ€treated inflammatory bowel disease patients. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1175-1181.	1.4	25
296	Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information. AAPS Journal, 2019, 21, 10.	2.2	13
297	Optimising infliximab induction dosing for patients with ulcerative colitis. British Journal of Clinical Pharmacology, 2019, 85, 782-795.	1.1	27
298	Gene and Mirna Regulatory Networks During Different Stages of Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2019, 13, 916-930.	0.6	41
299	Impact of endoscopy system, high definition, and virtual chromoendoscopy in daily routine colonoscopy: a randomized trial. Endoscopy, 2019, 51, 237-243.	1.0	23
300	GlycA, a Nuclear Magnetic Resonance Spectroscopy Measure for Protein Glycosylation, is a Viable Biomarker for Disease Activity in IBD. Journal of Crohn's and Colitis, 2019, 13, 389-394.	0.6	32
301	Vedolizumab in Refractory Microscopic Colitis: An International Case Series. Journal of Crohn's and Colitis, 2019, 13, 337-340.	0.6	37
302	Difference in Pathomechanism Between Crohnâ€™s Disease and Ulcerative Colitis Revealed by Colon Transcriptome. Inflammatory Bowel Diseases, 2019, 25, 722-731.	0.9	22
303	Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. Clinical Gastroenterology and Hepatology, 2019, 17, 1673-1679.e1.	2.4	26
304	Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab. Journal of Crohn's and Colitis, 2019, 13, 12-18.	0.6	47
305	Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohnâ€™s disease (ANDANTE I and II). Gut, 2019, 68, 40-48.	6.1	132
306	AUTOMATED REAL TIME ENDOSCOPIC SCORING BASED ON MACHINE LEARNING IN ULCERATIVE COLITIS: RED DENSITY RELIABILITY AND RESPONSIVENESS STUDY. Endoscopy, 2019, 51, .	1.0	0

#	ARTICLE	IF	CITATIONS
307	Burden of Ulcerative Colitis on Functioning and Well-being: A Systematic Literature Review of the SF-36® Health Survey. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 600-609.	0.6	48
308	P046 HISTOLOGIC MEASURES OF MUCOSAL HEALING CORRELATE WITH ENDOSCOPIC MEASURES OF DISEASE ACTIVITY AT BASELINE AND FOLLOWING INDUCTION THERAPY WITH THE JANUS KINASE 1 INHIBITOR FILGOTINIB IN ACTIVE CROHN'S DISEASE: RESULTS FROM FITZROY STUDY. <i>Gastroenterology</i> , 2018, 154, S24.	0.6	2
309	Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. <i>Gastroenterology</i> , 2018, 154, 1343-1351.e1.	0.6	240
310	Immunogenicity of biologics in inflammatory bowel disease. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 1756283X1775035.	1.4	168
311	Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 773-783.	1.9	7
312	Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1276-1283.e1.	2.4	39
313	Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease: an International, Cross-disciplinary Consensus. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 408-418.	0.6	102
314	DOP005 Safety of vedolizumab in patients naïve to treatment with TNF antagonists compared with patients with prior use of TNF antagonists. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S032-S034.	0.6	2
315	Analysis of Genes Associated With Monogenic Primary Immunodeficiency Identifies Rare Variants in XIAP in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018, 154, 2165-2177.	0.6	26
316	Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. <i>Gastroenterology</i> , 2018, 155, 76-87.	0.6	34
317	DOP046 Higher serum concentrations of vedolizumab are associated with superior endoscopic outcomes in Crohn's disease: data from the LOVE-CD trial. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S063-S063.	0.6	8
318	New treatment options for inflammatory bowel diseases. <i>Journal of Gastroenterology</i> , 2018, 53, 585-590.	2.3	142
319	Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial. <i>Gut</i> , 2018, 67, 818-826.	6.1	88
320	Effect of vedolizumab (anti- $\alpha_4\beta_7$ -integrin) therapy on histological healing and mucosal gene expression in patients with UC. <i>Gut</i> , 2018, 67, 43-52.	6.1	137
321	Development and validation of an optical biosensor for rapid monitoring of adalimumab in serum of patients with Crohn's disease. <i>Drug Testing and Analysis</i> , 2018, 10, 592-596.	1.6	30
322	Biopsy-derived Intestinal Epithelial Cell Cultures for Pathway-based Stratification of Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 178-187.	0.6	13
323	Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 145-156.	0.6	80
324	Outcome of restorative proctocolectomy with an ileoanal pouch for ulcerative colitis: effect of changes in clinical practice. <i>Colorectal Disease</i> , 2018, 20, O30-O38.	0.7	16

#	ARTICLE	IF	CITATIONS
325	Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating Î² <sup>27+</sup> T Cells in Crohn's Disease: Report of the TOSCA Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 188-196.	0.6	24
326	Low eukaryotic viral richness is associated with faecal microbiota transplantation success in patients with UC. <i>Gut</i> , 2018, 67, 1558-1559.	6.1	46
327	Risk Stratification for Surgery in Stricturing Ileal Crohn's Disease: The BACARDI Risk Model. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 32-38.	0.6	33
328	Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists. <i>United European Gastroenterology Journal</i> , 2018, 6, 439-445.	1.6	13
329	Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 229-237.	1.9	40
330	Anti-Î³-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 346-355.	1.9	41
331	Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 185-196.	1.0	15
332	OP007 Detection of mucosal healing with a serum marker panel in adalimumab-treated patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S005-S005.	0.6	2
333	P046 HISTOLOGIC MEASURES OF MUCOSAL HEALING CORRELATE WITH ENDOSCOPIC MEASURES OF DISEASE ACTIVITY AT BASELINE AND FOLLOWING INDUCTION THERAPY WITH THE JANUS KINASE 1 INHIBITOR FILGOTINIB IN ACTIVE CROHN'S DISEASE: RESULTS FROM FITZROY STUDY. <i>Inflammatory Bowel Diseases</i> , 2018, 24, S16-S17.	0.9	3
334	P035 Serum markers predict outcome to ustekinumab in patients with refractory Crohn's disease and provide insights in the mechanism of action. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S110-S110.	0.6	1
335	P330 A prospective trial to evaluate the feasibility of a mobile app in patients with inflammatory bowel disease under maintenance therapy. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S269-S269.	0.6	0
336	PTU-003...Filgotinib decreases inflammatory markers associated with endoscopic improvement in moderate to severely active Crohn's disease. , 2018, , .		0
337	Effects of Epithelial IL-13RÎ±2 Expression in Inflammatory Bowel Disease. <i>Frontiers in Immunology</i> , 2018, 9, 2983.	2.2	17
338	P042 Decreased leukocyte trafficking may contribute to vedolizumab refractory disease after anti-TNF exposure in patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S113-S113.	0.6	0
339	P117 Serum proteomic analysis characterises newly diagnosed Crohn's disease and ulcerative colitis depending on the age at diagnosis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S151-S152.	0.6	0
340	When IBD is not IBD. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1085-1088.	0.6	7
341	Reply. <i>Gastroenterology</i> , 2018, 155, 1278-1279.	0.6	0
342	Multimomics Analyses to Deliver the Most Effective Treatment to Every Patient With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2018, 155, e1-e4.	0.6	24



#	ARTICLE	IF	CITATIONS
343	Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study. Patient Preference and Adherence, 2018, Volume 12, 1193-1202.	0.8	38
344	Comparisons of gut microbiota profiles in wild-type and gelatinase B/matrix metalloproteinase-9-deficient mice in acute DSS-induced colitis. Npj Biofilms and Microbiomes, 2018, 4, 18.	2.9	10
345	Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, 1316-1325.	0.6	47
346	Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2018, 16, 1937-1946.e8.	2.4	113
347	Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. Inflammatory Bowel Diseases, 2018, 24, 2258-2265.	0.9	175
348	P045 Dried blood spot sampling can facilitate therapeutic drug monitoring of vedolizumab therapy. Journal of Crohn's and Colitis, 2018, 12, S114-S115.	0.6	0
349	Autologous Haematopoietic Stem Cell Transplantation for Crohn's Disease: A Retrospective Survey of Long-term Outcomes From the European Society for Blood and Marrow Transplantation. Journal of Crohn's and Colitis, 2018, 12, 1097-1103.	0.6	29
350	Defining Endoscopic Remission in Ileocolonic Crohn's Disease: Let's Start from Scratch. Journal of Crohn's and Colitis, 2018, 12, 1245-1248.	0.6	24
351	Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naïve Crohn's disease patients: the usefulness of rapid testing. Alimentary Pharmacology and Therapeutics, 2018, 48, 731-739.	1.9	62
352	Differential diagnosis of inflammatory bowel disease: imitations and complications. The Lancet Gastroenterology and Hepatology, 2018, 3, 644-653.	3.7	88
353	Prognostic value of histological activity in patients with ulcerative colitis in deep remission: A prospective multicenter study. United European Gastroenterology Journal, 2018, 6, 765-772.	1.6	53
354	TNF-anti-TNF Immune Complexes Inhibit IL-12/IL-23 Secretion by Inflammatory Macrophages via an Fc-dependent Mechanism. Journal of Crohn's and Colitis, 2018, 12, 1122-1130.	0.6	25
355	IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes. Nature Communications, 2018, 9, 2427.	5.8	159
356	Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study. Journal of Crohn's and Colitis, 2018, 12, 1158-1169.	0.6	95
357	Inherited p40phox deficiency differs from classic chronic granulomatous disease. Journal of Clinical Investigation, 2018, 128, 3957-3975.	3.9	99
358	Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized Treatment. Current Drug Targets, 2018, 19, 757-776.	1.0	13
359	Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD). Acta Gastro-Enterologica Belgica, 2018, 81, 49-53.	0.4	1
360	Long-term Efficacy of Vedolizumab for Crohn's Disease. Journal of Crohn's and Colitis, 2017, 11, jjw176.	0.6	141

#	ARTICLE	IF	CITATIONS
361	Long-term Efficacy of Vedolizumab for Ulcerative Colitis. Journal of Crohn's and Colitis, 2017, 11, jjw177.	0.6	140
362	A Simplified Geboes Score for Ulcerative Colitis. Journal of Crohn's and Colitis, 2017, 11, jjw154.	0.6	44
363	Specific members of the predominant gut microbiota predict pouchitis following colectomy and IPAA in UC. Gut, 2017, 66, 79-88.	6.1	114
364	Validation of a sample pretreatment protocol to convert a drug-sensitive into a drug-tolerant anti-Infliximab antibody immunoassay. Drug Testing and Analysis, 2017, 9, 243-247.	1.6	24
365	Immunoassay for Detection of Infliximab in Whole Blood Using a Fiber-Optic Surface Plasmon Resonance Biosensor. Analytical Chemistry, 2017, 89, 3664-3671.	3.2	65
366	Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut, 2017, 66, 1049-1059.	6.1	274
367	Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 941-950.	1.9	106
368	Epithelial organoid cultures from patients with ulcerative colitis and Crohn's disease: a truly long-term model to study the molecular basis for inflammatory bowel disease?. Gut, 2017, 66, 2193-2195.	6.1	43
369	Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control study. Alimentary Pharmacology and Therapeutics, 2017, 45, 923-932.	1.9	28
370	A microbial signature for Crohn's disease. Gut, 2017, 66, 813-822.	6.1	657
371	Efficacy and Safety of Oral Tofacitinib as Maintenance Therapy in Patients with Moderate to Severe Ulcerative Colitis: Results from a Phase 3 Randomized Controlled Trial. Gastroenterology, 2017, 152, S199.	0.6	3
372	Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine, 2017, 376, 1723-1736.	13.9	1,232
373	Therapeutic Manipulation of the Gut Microbiota Through Diet to Reduce Intestinal Inflammation: Results from the FIT Trial. Gastroenterology, 2017, 152, S1.	0.6	5
374	Clinical Relevance of Detecting Anti-Infliximab Antibodies with a Drug-Tolerant Assay: Post-HOC Analysis of the Taxit Trial. Gastroenterology, 2017, 152, S38.	0.6	3
375	Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease. Scandinavian Journal of Gastroenterology, 2017, 52, 1086-1092.	0.6	32
376	Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus - A Multicenter Retrospective Study. Inflammatory Bowel Diseases, 2017, 23, 1605-1613.	0.9	27
377	Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet, The, 2017, 390, 135-144.	6.3	157
378	Intestinal Organoids Derived from Inflamed Tissues Reach Transcription Levels Comparable to Non-Inflamed Tissues and Healthy Controls. Gastroenterology, 2017, 152, S411-S412.	0.6	1

#	ARTICLE	IF	CITATIONS
379	Disease Course and Operative Risk after Diagnosis of Ileal Penetrating Crohn's Disease: A Cohort Study. <i>Gastroenterology</i> , 2017, 152, S1212.	0.6	0
380	Inhibition of gelatinase B/MMP-9 does not attenuate colitis in murine models of inflammatory bowel disease. <i>Nature Communications</i> , 2017, 8, 15384.	5.8	40
381	A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 809-821.	1.0	32
382	Biologic Therapy of Ulcerative Colitis: Natalizumab, Vedolizumab, Etrolizumab (rHUMab Beta 7), Anti-MAdCAM. , 2017, , 449-454.		0
383	Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn's Disease and Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1085-1089.	0.6	58
384	Novel Targeted Therapies for Inflammatory Bowel Disease. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 127-142.	4.0	142
385	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. <i>Nature Genetics</i> , 2017, 49, 269-273.	9.4	230
386	Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 The, 2017, 389, 266-275.	6.3	353
387	Human intestinal epithelium in a dish: Current models for research into gastrointestinal pathophysiology. <i>United European Gastroenterology Journal</i> , 2017, 5, 1073-1081.	1.6	35
388	Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over Time. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 2202-2208.	0.9	31
389	AODWE-004â€¦Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis. , 2017, , .		0
390	Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 627-644.	1.0	24
391	Genetic and Transcriptomic Bases of Intestinal Epithelial Barrier Dysfunction in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1718-1729.	0.9	156
392	Long-term Outcomes with Anti-TNF Therapy and Accelerated Step-up in the Prospective Pediatric Belgian Crohn's Disease Registry (BELCRO). <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1584-1591.	0.9	7
393	Early Fibrostenosis in Crohn's Disease is Associated with Multiple Susceptibility Loci on ImmunoChip Analysis. <i>Gastroenterology</i> , 2017, 152, S982.	0.6	1
394	Defining Patient-Centered Outcomes for IBD and an International, Cross-Disciplinary Consensus. <i>Gastroenterology</i> , 2017, 152, S137-S138.	0.6	1
395	Efficacy and Safety of Abilumab in Subjects with Moderate to Severe Ulcerative Colitis: Results of a Phase 2B, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study. <i>Gastroenterology</i> , 2017, 152, S198.	0.6	8
396	The SF-36® Health Survey Distinguishes Disease Burden on Functioning and Well-Being Between Patients with Active vs Inactive Ulcerative Colitis. <i>Gastroenterology</i> , 2017, 152, S338.	0.6	0

#	ARTICLE	IF	CITATIONS
397	The Modified Postoperative Endoscopic Recurrence Score for Crohn's Disease: Does it Really Make a Difference in Predicting Clinical Recurrence?. Gastroenterology, 2017, 152, S376.	0.6	3
398	Application of Dried Blood Spots for Pharmacokinetic Profiling of Golimumab-Treated Patients with Ulcerative Colitis. Gastroenterology, 2017, 152, S382-S383.	0.6	0
399	Anti-Infliximab Antibody Concentrations Guide Therapeutic Decision-Making in Patients with Crohn's Disease Losing Clinical Response. Gastroenterology, 2017, 152, S392-S393.	0.6	0
400	Successful Dose De-Escalation to Adalimumab 40 mg Every Three Weeks in Patients with Crohn's Disease. Gastroenterology, 2017, 152, S406-S407.	0.6	0
401	Maintenance of Quality of Life Improvement in a Phase 3 Study of Tofacitinib for Patients with Moderately to Severely Active Ulcerative Colitis. Gastroenterology, 2017, 152, S601-S602.	0.6	9
402	Matrix Metalloproteinase/MMP-9 Gene Knockout does not Influence Changes in Gut Microbiota in a Model of Acute Dextran Sodium Sulphate/DSS-Induced Colitis. Gastroenterology, 2017, 152, S623.	0.6	1
403	Impact of Ileocecal Resection in Crohn's Disease Patients on Fecal Microbiota. Gastroenterology, 2017, 152, S989-S990.	0.6	0
404	Profiling of the Fecal Microbiota and Metabolome in Patients with Inflammatory Bowel Disease and their Unaffected Relatives. Gastroenterology, 2017, 152, S991.	0.6	0
405	Molecular Profiling of Early Crohn's Disease Using the Post-Operative Recurrence Model. Gastroenterology, 2017, 152, S79-S80.	0.6	0
406	Recent Anti-TNF Exposure Predicts Lower Vedolizumab Trough Concentrations in Patients with Crohn Disease. Gastroenterology, 2017, 152, S380.	0.6	4
407	Filgotinib (GLPG0634, GS-6034), a JAK-1 Selective Inhibitor, Significantly Reduces gut Tissue pSTAT3 in Crohn's Disease Patients. Gastroenterology, 2017, 152, S602.	0.6	1
408	Genetic Defects in ER Stress and Autophagy Translate Into Increased Functional ER Stress Levels in Patients with Inflammatory Bowel Disease. Gastroenterology, 2017, 152, S963-S964.	0.6	1
409	Correlation of Durability of Response, Serum Trough Concentrations and Outcome Parameters: Long-Term Follow-up of the Trough Concentration Adapted Infliximab Treatment (TAXIT) Trial. Gastroenterology, 2017, 152, S39.	0.6	1
410	Investing in Workability of Patients with IBD: Results of a Pilot Project Activ84work (Activate for) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 2	0.6	1
411	Perioperative use of Vedolizumab is not Associated with Short-Term Postoperative Infectious Complications in Patients with Ulcerative Colitis Undergoing (Procto) Colectomy with Ileal Pouch-Anal Anastomosis. Gastroenterology, 2017, 152, S581-S582.	0.6	5
412	Efficacy of Filgotinib, a Selective jak1 Inhibitor, is Independent of Prior Anti-TNF Exposure: Subgroup Analysis of the Phase 2 Fitzroy Study in Moderate-To-Severe Crohn's Disease. Gastroenterology, 2017, 152, S597.	0.6	1
413	Histological Remission is Predictive of Improved Clinical Outcomes in Patients with Ulcerative Colitis: Results from the Touchstone ole. Gastroenterology, 2017, 152, S597-S598.	0.6	0
414	Long-Term Effectiveness and Safety of Vedolizumab in Patients with Ulcerative Colitis: 5-Year Cumulative Exposure of Gemini 1 Completers Rolling into the Gemini Open-Label Extension Study. Gastroenterology, 2017, 152, S602.	0.6	7

#	ARTICLE	IF	CITATIONS
415	Natural History of Dysplasia and Colorectal Cancer in Inflammatory Bowel Disease in Belgium Tertiary Care Centers. <i>Gastroenterology</i> , 2017, 152, S740-S741.	0.6	0
416	Serum Marker Panel for Early Detection of Endoscopic Healing with Infliximab in Patients with Ulcerative Colitis. <i>Gastroenterology</i> , 2017, 152, S768.	0.6	0
417	Centrally-Determined Standardization of Flow Cytometry Methods Reduces Inter-Laboratory Variation in a Prospective Multicenter Study. <i>Gastroenterology</i> , 2017, 152, S772.	0.6	0
418	Mucosal Recolonization after Ileocecal Resection Differs in Crohn's Disease Patients Developing Postoperative Recurrence. <i>Gastroenterology</i> , 2017, 152, S990.	0.6	0
419	Short- and medium-term outcomes following primary ileocaecal resection for Crohn's disease in two specialist centres. <i>British Journal of Surgery</i> , 2017, 104, 1713-1722.	0.1	91
420	DOP029 Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post-hoc analysis of the taxit trial. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S44-S45.	0.6	0
421	PR3-anti-neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 56, e27-e30.	1.4	16
422	Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 84-90.	0.8	6
423	Comparison of health-related quality of life and disability in ulcerative colitis patients following restorative proctocolectomy with ileal pouch-anal anastomosis versus anti-tumor necrosis factor therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 338-344.	0.8	20
424	Effects of Education and Information on Vaccination Behavior in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 318-324.	0.9	32
425	Review Article. Absent in melanoma 2 (AIM2) in the intestine: diverging actions with converging consequences. <i>Inflammasome</i> , 2017, 3, 1-9.	0.6	2
426	Quantitative microbiome profiling links gut community variation to microbial load. <i>Nature</i> , 2017, 551, 507-511.	13.7	791
427	NOD2 and bacterial recognition as therapeutic targets for Crohn's disease. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 1123-1139.	1.5	33
428	Increased Baseline TNF-Driven Pathways Observed in Patients with Crohn's Disease not Responding to Infliximab. <i>Gastroenterology</i> , 2017, 152, S767.	0.6	2
429	The intestinal barrier: a fundamental role in health and disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 821-834.	1.4	703
430	Antibodies Towards Vedolizumab Appear from Week 2 Onwards and Disappear upon Treatment. <i>Gastroenterology</i> , 2017, 152, S382.	0.6	0
431	Perioperative Use of Vedolizumab is not Associated with Postoperative Infectious Complications in Patients with Ulcerative Colitis Undergoing Colectomy. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1353-1361.	0.6	56
432	Fine-mapping inflammatory bowel disease loci to single-variant resolution. <i>Nature</i> , 2017, 547, 173-178.	13.7	473

#	ARTICLE	IF	CITATIONS
433	Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2017, 152, 374-388.e4.	0.6	108
434	Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease. Expert Opinion on Biological Therapy, 2017, 17, 31-47.	1.4	29
435	Submucosal Plexitis as a Predictive Factor for Postoperative Endoscopic Recurrence in Patients with Crohn's Disease Undergoing a Resection with Ileocolonic Anastomosis: Results from a Prospective Single-centre Study. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 212-220.	0.6	42
436	Prevention of Antidrug Antibody Formation to Infliximab in Crohn's Patients With Prior Failure of Thiopurines. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 69-75.	2.4	24
437	Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 229-239.e5.	2.4	164
438	Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 53-59.	0.6	57
439	DOP028 Antibodies towards vedolizumab appear from week 2 onwards and disappear upon treatment. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S44-S44.	0.6	0
440	Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter Study. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e126.	1.3	10
441	P078 Gut microbiome profiling of MMP-9 deficient mice and their wild-type littermates in a model of acute DSS-induced colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S116-S117.	0.6	1
442	P382 A panel of serum markers for early detection of endoscopic healing with infliximab in patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S271-S272.	0.6	0
443	DOP047 Early fibrostenosis in Crohn's disease is associated with multiple susceptibility loci on Immunochip analysis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S54-S55.	0.6	0
444	P035 TNF-driven pathways are increased at baseline in Crohn's disease patients not responding to infliximab. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S96-S97.	0.6	0
445	P686 Application of dried blood spots for pharmacokinetic profiling of golimumab-treated patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S430-S431.	0.6	0
446	Safety and Efficacy of Long-term Treatment With Ozanimod: An Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis - TOUCHSTONE Extension 2-Year Follow-up. <i>American Journal of Gastroenterology</i> , 2017, 112, S321.	0.2	4
447	Tofacitinib for Maintenance Therapy in Patients With Active Ulcerative Colitis in the Phase 3 OCTAVE Sustain Trial: Results by Local and Central Endoscopic Assessments. <i>American Journal of Gastroenterology</i> , 2017, 112, S329-S330.	0.2	4
448	Assessing the Variability Between Endoscopic Scoring Indices for Evaluation of Crohn's Disease Activity. <i>American Journal of Gastroenterology</i> , 2017, 112, S426-S427.	0.2	0
449	A Non-Invasive Serological Test to Assess the Efficacy of Biologic and Non-Biologic Therapies on the Mucosal Health of Patients With Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2017, 112, S401-S402.	0.2	0
450	A Novel Serum Test to Describe the Mucosal Healing State by Disease Location in Crohn's Disease Patients. <i>American Journal of Gastroenterology</i> , 2017, 112, S321-S322.	0.2	0



#	ARTICLE	IF	CITATIONS
451	Development and Validation of a Multi-marker Serum Test for the Assessment of Mucosal Healing in Crohn's Disease Patients. American Journal of Gastroenterology, 2017, 112, S324.	0.2	1
452	Patients with High Anti-drug Antibody Titers Require a Higher Cumulative Infliximab Dose to Achieve Target Drug Concentrations: A Post-hoc Analysis of the TAXIT Trial. American Journal of Gastroenterology, 2016, 111, S319.	0.2	1
453	Systematic Literature Review on the Immunogenicity of Biologics in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2016, 111, S410.	0.2	1
454	Thromboembolism as an important complication of inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2016, 28, 1-7.	0.8	43
455	Genome-Wide Copy Number Variation Scan Identifies Complement Component C4 as Novel Susceptibility Gene for Crohn's Disease. Inflammatory Bowel Diseases, 2016, 22, 505-515.	0.9	12
456	Use of Placebo in Pediatric Inflammatory Bowel Diseases. Journal of Pediatric Gastroenterology and Nutrition, 2016, 62, 183-187.	0.9	33
457	Paediatric Crohn Disease. Journal of Pediatric Gastroenterology and Nutrition, 2016, 63, 253-258.	0.9	8
458	Patients with large-duct primary sclerosing cholangitis and Crohn's disease have a better outcome than those with ulcerative colitis, or without <scp>IBD</scp>. Alimentary Pharmacology and Therapeutics, 2016, 43, 612-620.	1.9	45
459	Identification of an inflammatory bowel disease patient with a deep vein thrombosis and an altered clot lysis profile. Blood Coagulation and Fibrinolysis, 2016, 27, 223-225.	0.5	3
460	The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases. Critical Reviews in Biochemistry and Molecular Biology, 2016, 51, 295-358.	2.3	62
461	OC-005â€¦A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A Human IL-12/23P40 MAB, in Moderate-Severe Crohn's Disease (CD) Refractory to anti-TNF: UNITI-1. Gut, 2016, 65, A3.2-A4.	6.1	0
462	Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation. Clinical and Translational Gastroenterology, 2016, 7, e206.	1.3	52
463	Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut, 2016, 65, 1681-1689.	6.1	312
464	Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab. Journal of Crohn's and Colitis, 2016, 10, 1015-1023.	0.6	66
465	Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays. Journal of Pharmaceutical and Biomedical Analysis, 2016, 125, 62-67.	1.4	29
466	O-001â€¦A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohn's Disease Refractory to Anti-TNF. Inflammatory Bowel Diseases, 2016, 22, S1.	0.9	42
467	697 Analytical and Clinical Validation of a Rapid Point-of-Care Assay for Infliximab Quantification in Patients With Ulcerative Colitis. Gastroenterology, 2016, 150, S145.	0.6	1
468	995 Effects of Education and Information on Vaccination Behavior in IBD Patients. Gastroenterology, 2016, 150, S204.	0.6	0

#	ARTICLE	IF	CITATIONS
469	Sa1825 Intestinal Organoids Derived From Patients With Inflammatory Bowel Disease Show Unaltered Transcriptional Profiles When Compared to Healthy Controls. <i>Gastroenterology</i> , 2016, 150, S374.	0.6	0
470	Mo1880 Mucosal Healing and Dysplasia Surveillance in a Large Referral Center Cohort of Patients With Crohn's Disease and Ulcerative Colitis Treated With Vedolizumab. <i>Gastroenterology</i> , 2016, 150, S804.	0.6	2
471	Tu1713 Host-Microbiome Interactions in Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2016, 150, S927-S928.	0.6	0
472	692 Drug-Level Based Dosing Versus Symptom-Based Dose Adaptation in Patients With Crohn's Disease: A Prospective, Randomized Multicenter Study (TAILORIX). <i>Gastroenterology</i> , 2016, 150, S143.	0.6	16
473	857 Ozanimod Induces Histological Response and Remission: Results From the TOUCHSTONE Study, a Randomized, Double-Blind, Placebo-Controlled Trial of Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, S183.	0.6	2
474	Su1909 Genetic Risk for Crohn's Disease has Little Impact on Intestinal Microbiota Composition. <i>Gastroenterology</i> , 2016, 150, S585-S586.	0.6	0
475	Tu1887 Revised Roles of Matrix Metalloproteinase/MMP-9 in Inflammatory Bowel Diseases/IBD: From Target to Biomarker. <i>Gastroenterology</i> , 2016, 150, S968.	0.6	0
476	694 A Variable Number of Tandem Repeat Polymorphism in the Promotor Region of the Neonatal FC Receptor Affects Anti-TNF Serum Levels in IBD. <i>Gastroenterology</i> , 2016, 150, S144.	0.6	1
477	Sa1956 Post-Induction Adalimumab Concentration Threshold Is Associated With Short-Term Mucosal Healing in Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, S415-S416.	0.6	1
478	A Method to Exploit the Structure of Genetic Ancestry Space to Enhance Case-Control Studies. <i>American Journal of Human Genetics</i> , 2016, 98, 857-868.	2.6	21
479	How Failure Can Fuel Improvements in Early Drug Development for Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2016, 150, 1061-1066.	0.6	2
480	Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2016, 374, 1754-1762.	13.9	361
481	Sarcoidosis-Like Lesions: Another Paradoxical Reaction to Anti-TNF Therapy?. <i>Journal of Crohn's and Colitis</i> , 2016, 11, jiw155.	0.6	35
482	Drug Development for Inflammatory Bowel Disease: Interaction Among Academia, Industry and Regulatory Authorities. <i>Journal of Crohn's and Colitis</i> , 2016, 10, S541-S541.	0.6	1
483	A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, 1599-1607.	0.2	300
484	Therapeutic innovations in inflammatory bowel diseases. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 49-58.	2.3	16
485	Magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with Crohn's disease, and may help select subjects with active inflammation. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 61-72.	1.9	60
486	A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, 1438-1445.	0.2	50

#	ARTICLE	IF	CITATIONS
487	A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis. <i>Nature Communications</i> , 2016, 7, 12342.	5.8	50
488	Bacteriome and Mycobiome Interactions Underscore Microbial Dysbiosis in Familial Crohn's Disease. <i>MBio</i> , 2016, 7, .	1.8	335
489	Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 673-683.	1.9	42
490	Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. <i>New England Journal of Medicine</i> , 2016, 375, 1946-1960.	13.9	1,316
491	Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease. <i>Annals of Internal Medicine</i> , 2016, 164, 10.	2.0	111
492	The Next Wave of Biological Agents for the Treatment of IBD. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1737-1743.	0.9	8
493	Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2711-2723.	0.9	14
494	Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 969-975.	0.9	44
495	Genetic Deletion of Tissue Inhibitor of Metalloproteinase-1/TIMP-1 Alters Inflammation and Attenuates Fibrosis in Dextran Sodium Sulphate-induced Murine Models of Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1336-1350.	0.6	34
496	812c Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor, Induces Clinical Remission in Patients With Moderate-to-Severe Crohn's Disease: Results From the Phase 2 FITZROY Study Interim Analysis. <i>Gastroenterology</i> , 2016, 150, S1267.	0.6	11
497	Sa1423 Correlation of Small Intestinal Permeability, Faecal Calprotectin and Barrier Genes in Multiple-Affected Families With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2016, 150, S311.	0.6	0
498	Sa1821 Functional Translation of IBD-Associated Genetic Variation in Patient-Derived Intestinal Epithelial Cells. <i>Gastroenterology</i> , 2016, 150, S373.	0.6	0
499	Sa1943 Variability in Vedolizumab Exposure Between Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2016, 150, S411-S412.	0.6	0
500	Mo1879 Response and Remission Rates With Up to 3 Years of Vedolizumab Treatment in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2016, 150, S803-S804.	0.6	1
501	764 Results of Andante, a Randomized Clinical Study With an Anti-IL6 Antibody (PF-04236921) in Subjects With Crohn's Disease Who Are Anti-TNF Inadequate Responders. <i>Gastroenterology</i> , 2016, 150, S155.	0.6	6
502	855 Efficacy and Safety of Tofacitinib for Oral Induction Therapy in Patients With Moderate to Severe Crohn's Disease: Results of a Phase 2B Randomized Placebo-Controlled Trial. <i>Gastroenterology</i> , 2016, 150, S182-S183.	0.6	11
503	Su1814 The Need for Surgery in Stricturing Ileal CD Is Linked to Clinical and Imaging Factors But Independent of NOD2 Genotype. <i>Gastroenterology</i> , 2016, 150, S560.	0.6	2
504	Tu1943 Validation of the Simplified Geboes Score for Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, S985.	0.6	0

#	ARTICLE	IF	CITATIONS
505	Variability in Golimumab Exposure: A "Real-Life" Observational Study in Active Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 575-581.	0.6	71
506	Concordance in Anti-OmpC and Anti-I2 Indicate the Influence of Genetic Predisposition: Results of a European Study of Twins with Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 695-702.	0.6	13
507	Treat to Target in Inflammatory Bowel Disease. <i>Current Treatment Options in Gastroenterology</i> , 2016, 14, 61-72.	0.3	29
508	Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 543-549.	2.4	154
509	P-106 Examination of an Alternative Definition for Clinical Remission in UC. <i>Inflammatory Bowel Diseases</i> , 2016, 22, S43.	0.9	0
510	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. <i>Gastroenterology</i> , 2016, 150, 1568-1578.	0.6	251
511	Association Between Response to Etrolizumab and Expression of Integrin $\alpha$ 4 $\beta$ 7 and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 477-487.e9.	0.6	133
512	Fiber optic-SPR platform for fast and sensitive infliximab detection in serum of inflammatory bowel disease patients. <i>Biosensors and Bioelectronics</i> , 2016, 79, 173-179.	5.3	104
513	Modified Side-To-Side Isoperistaltic Strictureplasty over the Ileocaecal Valve: An Alternative to Ileocaecal Resection in Extensive Terminal Ileal Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 437-442.	0.6	37
514	Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2016, 150, 875-887.e9.	0.6	263
515	IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. <i>Gut</i> , 2016, 65, 1447-1455.	6.1	155
516	Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 387-394.	0.6	256
517	Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. <i>Lancet</i> , The, 2016, 387, 156-167.	6.3	607
518	Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial. <i>Gut</i> , 2016, 65, 1126-1131.	6.1	82
519	Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 348-354.e17.	2.4	309
520	Covariates Influencing the Exposure-Response Relationship for Certolizumab Pegol During the Induction and Maintenance Phases in Patients with Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, S262-S263.	0.2	2
521	Tofacitinib for Induction Therapy in Patients with Active Ulcerative Colitis in Two Phase 3 Clinical Trials: Results by Local and Central Endoscopic Assessments. <i>American Journal of Gastroenterology</i> , 2016, 111, S319-S320.	0.2	2
522	Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer. <i>Annals of Gastroenterology</i> , 2016, 29, 127-36.	0.4	8

#	ARTICLE	IF	CITATIONS
523	Safety and Efficacy of Long-Term Treatment with Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis: Touchstone Extension. <i>American Journal of Gastroenterology</i> , 2016, 111, S262.	0.2	0
524	Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 479-485.	1.0	37
525	An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2172-2177.	0.9	35
526	Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1170-1181.	1.9	86
527	Strong Upregulation of AIM2 and IFI16 Inflammasomes in the Mucosa of Patients with Active Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2673-2682.	0.9	94
528	Anti-Tumor Necrosis Factor Therapy Restores Peripheral Blood B-cell Subsets and CD40 Expression in Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2787-2796.	0.9	31
529	Smoking behaviour and knowledge of the health effects of smoking in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1294-1302.	1.9	26
530	Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 441-451.	1.9	148
531	The genetic architecture of inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 2015, Publish Ahead of Print, 456-63.	1.0	27
532	Etrolizumab Treatment Increases Blood Levels of CD3, Treg, and Th17 Cells Measured Through Epigenetic Activation of CD3, FoxP3 and IL-17 Loci. <i>American Journal of Gastroenterology</i> , 2015, 110, S777.	0.2	0
533	Withdrawal of anti-tumour necrosis factor ± therapy in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 4773.	1.4	29
534	Restoration of Foxp3+ Regulatory T-cell Subsets and Foxp3 <sup>hi</sup> Type 1 Regulatory-like T Cells in Inflammatory Bowel Diseases During Anti-tumor Necrosis Factor Therapy. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	0.9	14
535	Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2015, 148, 1320-1329.e3.	0.6	745
536	Systematic versus Endoscopy-driven Treatment with Azathioprine to Prevent Postoperative Ileal Crohn's Disease Recurrence. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 617-624.	0.6	44
537	Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 601-606.	0.6	81
538	The Occurrence of Thrombosis in Inflammatory Bowel Disease Is Reflected in the Clot Lysis Profile. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2540-2548.	0.9	13
539	Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1158-1169.	1.9	49
540	High Anti-Tumour Necrosis Factor Trough Concentrations – Only a Cost Issue or Also Hidden Dangers Ahead?. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 943-944.	0.6	3

#	ARTICLE	IF	CITATIONS
541	Proteolytic Cleavage and Loss of Function of Biologic Agents That Neutralize Tumor Necrosis Factor in the Mucosa of Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2015, 149, 1564-1574.e3.	0.6	105
542	Long-Term Outcome of Patients With Crohn's Disease Who Discontinued Infliximab Therapy Upon Clinical Remission. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1103-1110.	2.4	76
543	Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 514-521.e4.	2.4	116
544	Polymorphisms Near TBX5 and GDF7 Are Associated With Increased Risk for Barrett's Esophagus. <i>Gastroenterology</i> , 2015, 148, 367-378.	0.6	93
545	Pharmacokinetics of adalimumab in Crohn's disease. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1155-1157.	0.8	35
546	The Modified Mayo Endoscopic Score (MMES): A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis Patients. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 846-852.	0.6	108
547	Differences between adults and children: genetics and beyond. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 191-196.	1.4	6
548	The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. <i>Gut</i> , 2015, 64, 1539-1545.	6.1	239
549	445 The TOUCHSTONE Study: a Randomized, Double-Blind, Placebo-Controlled Induction Trial of an Oral S1P Receptor Modulator (RPC1063) in Moderate to Severe Ulcerative Colitis. <i>Gastrointestinal Endoscopy</i> , 2015, 81, AB147.	0.5	5
550	Oral SMAD7 Antisense Drug for Crohn's Disease. <i>New England Journal of Medicine</i> , 2015, 372, 1166-1167.	13.9	19
551	Short-term Effect of Infliximab Is Reflected in the Clot Lysis Profile of Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 570-578.	0.9	25
552	Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 182-197.	0.9	182
553	Aeromonas Species. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 71-78.	0.9	26
554	Postoperative Inflammatory Response in Crohn's Patients: A Comparative Study. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 1127-1131.	0.6	18
555	A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 1120-1126.	0.6	50
556	Immunogenicity to infliximab is associated with HLA-DRB1. <i>Gut</i> , 2015, 64, 1344-1345.	6.1	57
557	Serum Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Marker for Mucosal Healing in Patients with Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 1079-1087.	0.6	39
558	Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. <i>Lancet</i> , The, 2015, 386, 1825-1834.	6.3	354



#	ARTICLE	IF	CITATIONS
559	Reply. Clinical Gastroenterology and Hepatology, 2015, 13, 1705-1706.	2.4	0
560	A Rule for Determining Risk of Colorectal Cancer in Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 148-154.e1.	2.4	30
561	A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2015, 13, 531-538.	2.4	158
562	Faecal metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD. Gut, 2015, 64, 447-458.	6.1	185
563	Outcome measures for clinical trials in paediatric IBD: an evidence-based, expert-driven practical statement paper of the paediatric ECCO committee. Gut, 2015, 64, 438-446.	6.1	72
564	Vedolizumab Exposure in Pregnancy: Outcomes From Clinical Studies in Ulcerative Colitis and Crohn's Disease. American Journal of Gastroenterology, 2015, 110, S771-S772.	0.2	5
565	Defining Remission Using Patient-reported Outcome Components of the Crohn's Disease Activity Index: Post-hoc Analyses of Vedolizumab Data from the GEMINI 2 Study. American Journal of Gastroenterology, 2015, 110, S792-S793.	0.2	0
566	A Randomized, Double-Blind, Placebo-Controlled Trial of Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis: Results of the Maintenance Period of the TOUCHSTONE Study. American Journal of Gastroenterology, 2015, 110, S783.	0.2	1
567	Effects of Increased Vedolizumab Dosing Frequency on Disease Activity in Ulcerative Colitis and Crohn's Disease. American Journal of Gastroenterology, 2014, 109, S478-S479.	0.2	5
568	Progress towards butyrate-producing probiotics: <i>Butyrivibrio</i> <i>pullicaeorum</i> capsule and efficacy in TNBS models in comparison with therapeutics: Table 1. Gut, 2014, 63, 367-367.	6.1	30
569	Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target. Expert Review of Clinical Immunology, 2014, 10, 885-895.	1.3	9
570	Genetic variants in <i>CDC42</i> and <i>NXPH1</i> as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndrome. Gut, 2014, 63, 1103-1111.	6.1	49
571	C0477: Primary Response to Infliximab Therapy in IBD Patients is Reflected in the Normalisation of the Haemostatic Profile. Thrombosis Research, 2014, 133, S6-S7.	0.8	0
572	Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut, 2014, 63, 1721-1727.	6.1	336
573	Drug safety evaluation of certolizumab pegol. Expert Opinion on Drug Safety, 2014, 13, 255-266.	1.0	15
574	Genetic variation in the <i>lymphotoxin-<math>\alpha</math></i> ( <i>LTA</i> )/ <i>tumour necrosis factor-<math>\alpha</math></i> ( <i>TNF<math>\alpha</math></i> ) locus as a risk factor for idiopathic achalasia. Gut, 2014, 63, 1401-1409.	6.1	21
575	Development of a Universal Anti-Adalimumab Antibody Standard for Interlaboratory Harmonization. Therapeutic Drug Monitoring, 2014, 36, 669-673.	1.0	39
576	Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Serum Marker of Mucosal Healing in Ulcerative Colitis. Inflammatory Bowel Diseases, 2014, 20, 1198-1207.	0.9	47

#	ARTICLE	IF	CITATIONS
577	Small Bowel Adenocarcinomas Complicating Crohn's Disease Are Associated With Dysplasia. Inflammatory Bowel Diseases, 2014, 20, 1584-1592.	0.9	75
578	Infliximab Restores the Dysfunctional Matrix Remodeling Protein and Growth Factor Gene Expression in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2014, 20, 339-352.	0.9	36
579	Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2014, 40, 1324-1332.	1.9	64
580	Republished: Recent advances: personalised use of current Crohn's disease therapeutic options. Postgraduate Medical Journal, 2014, 90, 144-148.	0.9	0
581	IBD and health-related quality of life â Discovering the true impact. Journal of Crohn's and Colitis, 2014, 8, 1281-1286.	0.6	240
582	DOP063 Biomarker panel for prediction of mucosal healing in patients with Crohn's disease under infliximab therapy. Journal of Crohn's and Colitis, 2014, 8, S45-S46.	0.6	1
583	Tuberculosis infection following anti-TNF therapy in inflammatory bowel disease, despite negative screening. Journal of Crohn's and Colitis, 2014, 8, 550-557.	0.6	36
584	ABO histo-blood group might modulate predisposition to Crohn's disease and affect disease behavior. Journal of Crohn's and Colitis, 2014, 8, 489-494.	0.6	32
585	P285 Agreement among experts in the endoscopic evaluation of postoperative recurrence in Crohn's disease using the Rutgeerts score. Journal of Crohn's and Colitis, 2014, 8, S182.	0.6	2
586	Sa1237 Prediction of Primary Response to Infliximab in Crohn's Disease: A Matrix-Based Prediction Model. Gastroenterology, 2014, 146, S-239.	0.6	1
587	Autophagy and Crohn's Disease. , 2014, , 69-77.		1
588	P375 Primary response to infliximab therapy in IBD patients is reflected in the normalisation of the haemostatic profile. Journal of Crohn's and Colitis, 2014, 8, S221-S222.	0.6	0
589	Review article: anti-adhesion therapies for inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2014, 39, 579-594.	1.9	155
590	Targeting TNF-Î± for the treatment of inflammatory bowel disease. Expert Opinion on Biological Therapy, 2014, 14, 75-101.	1.4	119
591	Genetic and microbial factors modulating the ubiquitin proteasome system in inflammatory bowel disease. Gut, 2014, 63, 1265-1274.	6.1	72
592	A20 controls intestinal homeostasis through cell-specific activities. Nature Communications, 2014, 5, 5103.	5.8	109
593	Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Current State and Future Perspectives. Current Gastroenterology Reports, 2014, 16, 378.	1.1	86
594	DOP028 Development of red flags for early referral of adults with symptoms and signs suggestive of Crohn's disease: an IOIBD initiative. Journal of Crohn's and Colitis, 2014, 8, S28.	0.6	1

#	ARTICLE	IF	CITATIONS
595	Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. <i>Lancet</i> , The, 2014, 384, 309-318.	6.3	421
596	P055 Integrated miRNA and gene expression profiling in patients with ulcerative colitis before and after infliximab treatment. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S85-S86.	0.6	0
597	Long-term functional outcome after ileal pouch anal anastomosis in 191 patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1261-1266.	0.6	41
598	OP013 Status of ER stress and autophagy in Crohn's disease: From genetics to functional read-outs. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S8.	0.6	0
599	Genetic susceptibility and genotypeâ€“phenotype association in 588 Danish children with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 678-685.	0.6	26
600	DOP052 Active smoking, and pre-operative anti-flagellin Fla2 and pANCA antibodies may predict postoperative Crohn's disease recurrence: results from a prospective mono-centric trial. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S39-S40.	0.6	2
601	P096 Analysis of the tryptophan metabolism and indoleamine 2,3-dioxygenase expression (IDO) in patients with inflammatory bowel disease before and after infliximab treatment. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S102.	0.6	3
602	P338 Systematic versus endoscopy-driven treatment with azathioprine to prevent postoperative ileal Crohn's disease recurrence. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S205-S206.	0.6	2
603	DOP031 A multicenter study to evaluate magnetic resonance enterography (MRE) for selection of Crohn's disease patients for inclusion into a therapeutic clinical trial. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S29-S30.	0.6	0
604	DOP030 Feasibility, precision and reproducibility of MR enterography for detection of inflammation in Crohn's Disease in a multicenter clinical trial. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S29.	0.6	0
605	Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1474-1481.e2.	2.4	124
606	P589 The future of academic gastroenterology â€“ insights from a Europe-wide survey of trainees. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S314.	0.6	0
607	OP010 AlphaE integrin expression as a predictive biomarker for induction of clinical remission by etrolizumab: Analysis of a phase II trial in moderate-to-severely active ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S7.	0.6	2
608	P124 The Modified Mayo Endoscopic Score (MMES): a new score for the assessment of extent and severity of endoscopic activity in ulcerative colitis (UC) patients. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S113-S114.	0.6	0
609	P187 MRI T2 relaxometry to image fibrosis in patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S140.	0.6	1
610	OP007 Anti-MAdCAM monoclonal antibody PF-00547659 does not affect immune surveillance in the central nervous system of anti-TNF and immunosuppressant experienced Crohn's disease patients who are anti-TNF inadequate responders: Results from the TOSCA study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S4-S5.	0.6	9
611	P566 A matrix-based prediction model for primary response to infliximab in Crohn's disease patients. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S303-S304.	0.6	1
612	DOP024 Pregnancy outcomes after exposure to certolizumab pegol: Results from safety surveillance. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S26.	0.6	4

#	ARTICLE	IF	CITATIONS
613	P033 Prevention of recurrent <i>Clostridium difficile</i> infection by neutralizing monoclonal antibodies in a hamster relapse model. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S77-S78.	0.6	0
614	OC.03.6 GENETIC AND CLINICAL CHARACTERIZATION OF 43 MULTIPLE-AFFECTED INFLAMMATORY BOWEL DISEASE FAMILIES. <i>Digestive and Liver Disease</i> , 2014, 46, S10-S11.	0.4	0
615	OP004 Early combined immunosuppression for the management of Crohn's disease: A community-based cluster randomized trial. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S2-S3.	0.6	15
616	A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis. <i>Gut</i> , 2014, 63, 1275-1283.	6.1	1,353
617	Integrated miRNA and mRNA Expression Profiling in Inflamed Colon of Patients with Ulcerative Colitis. <i>PLoS ONE</i> , 2014, 9, e116117.	1.1	73
618	Infliximab for Ulcerative Colitis. , 2014, , 175-184.		0
619	Pregnancy Outcomes After Exposure to Certolizumab Pegol: Results From Safety Surveillance. <i>American Journal of Gastroenterology</i> , 2014, 109, S489.	0.2	0
620	Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of AVX-470, an Oral, Bovine-Derived Anti-TNF Antibody, in Patients With Active Ulcerative Colitis (UC): Initial Human Experience. <i>American Journal of Gastroenterology</i> , 2014, 109, S494-S495.	0.2	0
621	Neutralization of Membrane TNF, but Not Soluble TNF, Is Crucial for the Treatment of Experimental Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 246-253.	0.9	56
622	Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 950-957.	0.6	83
623	The Role of Centralized Reading of Endoscopy in a Randomized Controlled Trial of Mesalamine for Ulcerative Colitis. <i>Gastroenterology</i> , 2013, 145, 149-157.e2.	0.6	196
624	Association Between Variants of PRDM1 and NDP52 and Crohn's Disease, Based on Exome Sequencing and Functional Studies. <i>Gastroenterology</i> , 2013, 145, 339-347.	0.6	149
625	The role of Haptoglobin and its related protein, Zonulin, in inflammatory bowel disease. <i>Tissue Barriers</i> , 2013, 1, e27321.	1.6	121
626	Profile of pediatric Crohn's disease in Belgium. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e588-e598.	0.6	33
627	Recent advances: personalised use of current Crohn's disease therapeutic options. <i>Gut</i> , 2013, 62, 1511-1515.	6.1	30
628	Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project. <i>Gut</i> , 2013, 62, 1556-1565.	6.1	221
629	492 Trough Levels and Antidrug Antibodies Predict Safety and Success of Restarting Infliximab After a Long Drug Holiday. <i>Gastroenterology</i> , 2013, 144, S-91-S-92.	0.6	4
630	Su1204 Long-Term Outcome of Infliximab Therapy in Patients With Ulcerative Colitis: Identification of Predictors of Relapse-Free and Colectomy-Free Survival. <i>Gastroenterology</i> , 2013, 144, S-426.	0.6	4

#	ARTICLE	IF	CITATIONS
631	159 Differentiation Between Etrolizumab (Rhumab Beta7) and Placebo in the Eucalyptus Phase II Randomized Double-Blind Placebo-Controlled Induction Study to Evaluate Efficacy and Safety in Patients With Refractory Moderate-to-Severely Active Ulcerative Colitis. <i>Gastroenterology</i> , 2013, 144, S-36.	0.6	10
632	Su1753 Primary Response to Infliximab in Crohn's Disease Is Associated With the Tnfrsf1a Rs1800693 Gene Polymorphism. <i>Gastroenterology</i> , 2013, 144, S-467-S-468.	0.6	2
633	Anxiety is associated with impaired tolerance of colonoscopy preparation in inflammatory bowel disease and controls. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e580-e587.	0.6	35
634	Intersphincteric proctectomy with end-colostomy for anorectal Crohn's disease results in early and severe proximal colonic recurrence. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e227-e231.	0.6	22
635	Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient. <i>American Journal of Gastroenterology</i> , 2013, 108, 962-971.	0.2	312
636	Letter: detection of infliximab levels and anti-infliximab antibodies – comparison of three different assays; authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 282-282.	1.9	6
637	Interleukin-15 receptor $\alpha$ expression in inflammatory bowel disease patients before and after normalization of inflammation with infliximab. <i>Immunology</i> , 2013, 138, 47-56.	2.0	13
638	Genome-wide association analysis in Primary sclerosing cholangitis and ulcerative colitis identifies risk loci at <i>GPR35</i> and <i>TCF4</i> . <i>Hepatology</i> , 2013, 58, 1074-1083.	3.6	150
639	Autophagy: a new target or an old strategy for the treatment of Crohn's disease?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 395-401.	8.2	51
640	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. <i>Nature Genetics</i> , 2013, 45, 670-675.	9.4	339
641	Pathogenesis and management of IBD – thinking outside the box. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 67-69.	8.2	8
642	Value of drug level testing and antibody assays in optimising biological therapy. <i>Frontline Gastroenterology</i> , 2013, 4, 41-43.	0.9	30
643	Deep Resequencing of GWAS Loci Identifies Rare Variants in <i>CARD9</i> , <i>IL23R</i> and <i>RNF186</i> That Are Associated with Ulcerative Colitis. <i>PLoS Genetics</i> , 2013, 9, e1003723.	1.5	185
644	Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. <i>Gut</i> , 2013, 62, 201-208.	6.1	147
645	O-003 Y1 Drug Level Versus Clinically Based Dosing of Infliximab Maintenance Therapy In IBD. <i>Inflammatory Bowel Diseases</i> , 2013, 19, S2-S3.	0.9	5
646	Certolizumab pegol in the treatment of Crohn's disease. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 595-605.	1.4	5
647	Letter: dry blood spots for anti-TNF treatment monitoring in IBD. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 1024-1025.	1.9	7
648	<i>Butyrivibrio</i> <i>pulliaecorum</i> in inflammatory bowel disease. <i>Gut</i> , 2013, 62, 1745-1752.	6.1	319

#	ARTICLE	IF	CITATIONS
649	Genetic association and functional role of Crohn disease risk alleles involved in microbial sensing, autophagy, and endoplasmic reticulum (ER) stress. <i>Autophagy</i> , 2013, 9, 2046-2055.	4.3	54
650	5-Aminosalicylate is Not Protective From Neoplasia in Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2013, 108, 1015.	0.2	5
651	Metabolic Profiling of the Impact of Oligofructose-Enriched Inulin in Crohn's Disease Patients: A Double-Blinded Randomized Controlled Trial. <i>Clinical and Translational Gastroenterology</i> , 2013, 4, e30.	1.3	72
652	Correlation Between the Endoscopic and Histologic Score in Assessing the Activity of Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1194-1201.	0.9	111
653	Serum Adalimumab Concentration and Clinical Remission in Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1112-1122.	0.9	113
654	Reply to Falvey et al.. <i>Inflammatory Bowel Diseases</i> , 2013, 19, E81.	0.9	0
655	A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn's Disease. <i>PLoS ONE</i> , 2013, 8, e60094.	1.1	117
656	Unique Gene Expression and MR T2 Relaxometry Patterns Define Chronic Murine Dextran Sodium Sulphate Colitis as a Model for Connective Tissue Changes in Human Crohn's Disease. <i>PLoS ONE</i> , 2013, 8, e68876.	1.1	42
657	Infliximab Therapy for Pediatric Crohn Disease and Ulcerative Colitis. , 2013, , 345-355.		0
658	Molecular Profiling of IBD Subtypes/Response to Therapy. , 2013, , 151-169.		0
659	Association of a Functional Variant in the Wnt Co-Receptor LRP6 with Early Onset Ileal Crohn's Disease. <i>PLoS Genetics</i> , 2012, 8, e1002523.	1.5	44
660	Intestinal expression of SHIP in inflammatory bowel diseases. <i>Gut</i> , 2012, 61, 956-957.	6.1	14
661	Antibodies to GP2, the major zymogen granule membrane glycoprotein, in inflammatory bowel diseases. <i>Gut</i> , 2012, 61, 162.3-164.	6.1	44
662	Classification of inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 2012, 28, 321-326.	1.0	54
663	Effects of haptoglobin polymorphisms and deficiency on susceptibility to inflammatory bowel disease and on severity of murine colitis. <i>Gut</i> , 2012, 61, 528-534.	6.1	32
664	Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment: Table 1. <i>Gut</i> , 2012, 61, 321-321.	6.1	49
665	Assessment of the Microbiota in Microdissected Tissues of Crohn's Disease Patients. <i>International Journal of Inflammation</i> , 2012, 2012, 1-11.	0.9	9
666	Effect of oligofructose-enriched inulin (OF-IN) on bacterial composition and disease activity of patients with Crohn's disease: results from a double-blinded randomised controlled trial: Table 1. <i>Gut</i> , 2012, 61, 958-958.	6.1	90



#	ARTICLE	IF	CITATIONS
667	Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. <i>Gut</i> , 2012, 61, 229-234.	6.1	128
668	Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 765-771.	1.9	182
669	Management of inflammatory bowel disease in pregnancy. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 811-823.	0.6	75
670	Paradoxical inflammation induced by anti-TNF agents in patients with IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 496-503.	8.2	169
671	Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. <i>Journal of Hepatology</i> , 2012, 57, 366-375.	1.8	196
672	Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. <i>Nature</i> , 2012, 491, 119-124.	13.7	4,038
673	Towards a Novel Molecular Classification of IBD. <i>Digestive Diseases</i> , 2012, 30, 425-427.	0.8	16
674	OP10 Importance of trough levels and antibodies on the long-term efficacy of infliximab therapy in ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2012, 6, S5.	0.6	12
675	OP11 Individualised infliximab treatment using therapeutic drug monitoring: A prospective controlled Trough level Adapted infliximab Treatment (TAXIT) trial. <i>Journal of Crohn's and Colitis</i> , 2012, 6, S6.	0.6	30
676	P459 Predominant dysbiosis in patients with ulcerative colitis is different from Crohn's disease patients. <i>Journal of Crohn's and Colitis</i> , 2012, 6, S192.	0.6	1
677	Mo2083 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease. <i>Gastroenterology</i> , 2012, 143, e26.	0.6	77
678	Genetic variants in autophagy-related genes and granuloma formation in a cohort of surgically treated Crohn's disease patients. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 43-50.	0.6	43
679	Recommendations for the treatment of ulcerative colitis with infliximab: A gastroenterology expert group consensus. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 248-258.	0.6	38
680	Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 557-562.	0.6	129
681	Erratum to "Cancer in inflammatory bowel disease 15years after diagnosis in a population-based European Collaborative follow-up study" [J Crohns Colitis (2011) 5, 430-442]. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 132-133.	0.6	1
682	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 991-1030.	0.6	1,106
683	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 965-990.	0.6	715
684	S565 Novel Infliximab (IFX) and Antibody-to-Infliximab (ATI) Assays are Predictive of Disease Activity in Patients With Crohn's Disease (CD). <i>Gastroenterology</i> , 2012, 142, S-114.	0.6	29

#	ARTICLE	IF	CITATIONS
685	1159 Results on the Optimisation Phase of the Prospective Controlled Trough Level Adapted Infliximab Treatment (TAXIT) Trial. <i>Gastroenterology</i> , 2012, 142, S-211-S-212.	0.6	37
686	Prognostic Value of Serologic and Histologic Markers on Clinical Relapse in Ulcerative Colitis Patients With Mucosal Healing. <i>American Journal of Gastroenterology</i> , 2012, 107, 1684-1692.	0.2	234
687	Impaired butyrate oxidation in ulcerative colitis is due to decreased butyrate uptake and a defect in the oxidation pathway*. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1127-1136.	0.9	91
688	Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2218-2224.	0.9	662
689	Decreased mucosal sulfide detoxification is related to an impaired butyrate oxidation in ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2371-2380.	0.9	39
690	Malignancies and mortality in 200 patients with primary sclerosing cholangitis: a long-term single-centre study. <i>Liver International</i> , 2012, 32, 214-222.	1.9	79
691	Commentary: <sc>BMI</sc> and the need for adalimumab dose escalation in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 848-848.	1.9	1
692	Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 312-323.	1.9	75
693	Octreotide for the treatment of diarrhoea in patients with ileal pouch anal anastomosis: a placebo-controlled crossover study. <i>Colorectal Disease</i> , 2012, 14, e181-6.	0.7	13
694	Variants of NOD1 and NOD2 genes display opposite associations with familial risk of Crohn's disease and anti-saccharomyces cerevisiae antibody levels. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 430-438.	0.9	20
695	Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 401-408.	0.9	150
696	Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: An expert consensus report. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 152-160.	0.9	63
697	Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 421-427.e1.	2.4	174
698	Long-Term Monitoring of Infliximab Therapy for Perianal Fistulizing Crohn's Disease by Using Magnetic Resonance Imaging. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 130-136.e1.	2.4	92
699	Corrigendum to "Rectal non-Hodgkin's lymphoma in an infliximab treated patient with ulcerative colitis and primary sclerosing cholangitis" [J Crohn's and Colitis 4 (2010) 683-6]. Epub 2010 Jul 14]. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 79.	0.6	0
700	Managing the long term care of inflammatory bowel disease patients: The cost to European health care providers. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 301-316.	0.6	33
701	Cancer in inflammatory bowel disease 15years after diagnosis in a population-based European Collaborative follow-up study. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 430-442.	0.6	40
702	The Role of FC Gamma Receptor (FCGR) Mutations in the Response to Infliximab in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2011, 140, S-1.	0.6	3

#	ARTICLE	IF	CITATIONS
703	Mucosal Gene Expression of Cell Adhesion Molecules, Chemokines, and Chemokine Receptors in Patients With Inflammatory Bowel Disease Before and After Infliximab Treatment. <i>American Journal of Gastroenterology</i> , 2011, 106, 748-761.	0.2	121
704	The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response?. <i>American Journal of Gastroenterology</i> , 2011, 106, 199-212.	0.2	356
705	102 NOVEL SUSCEPTIBILITY LOCI FOR PRIMARY SCLEROSING CHOLANGITIS IDENTIFIED BY GENOME-WIDE ASSOCIATION AND REPLICATION ANALYSIS. <i>Journal of Hepatology</i> , 2011, 54, S46.	1.8	1
706	Inflammatory bowel disease and colitis: new concepts from the bench and the clinic. <i>Current Opinion in Gastroenterology</i> , 2011, 27, 32-37.	1.0	16
707	Crohn's disease patients with persistently elevated CRP plasma concentration have higher rates of remission with certolizumab pegol 400 mg every 2 weeks vs every 4 weeks. <i>Inflammatory Bowel Diseases</i> , 2011, 17, S21.	0.9	1
708	The butyrate producing <i>Clostridium</i> cluster IV genus <i>Butyrivibrio</i> has a decreased abundance in IBD stool samples and a comparative efficacy in TNBS models compared to currently available therapeutics. <i>Inflammatory Bowel Diseases</i> , 2011, 17, S65-S66.	0.9	5
709	Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 401-403.	1.9	9
710	FISH analysis of <i>Lactobacillus</i> biofilms in the gastrointestinal tract of different hosts. <i>Letters in Applied Microbiology</i> , 2011, 52, 220-226.	1.0	48
711	High-throughput method for comparative analysis of denaturing gradient gel electrophoresis profiles from human fecal samples reveals significant increases in two bifidobacterial species after inulin-type prebiotic intake. <i>FEMS Microbiology Ecology</i> , 2011, 75, 343-349.	1.3	37
712	Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. <i>Nature Genetics</i> , 2011, 43, 17-19.	9.4	221
713	Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. <i>Nature Genetics</i> , 2011, 43, 43-47.	9.4	175
714	Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. <i>Nature Genetics</i> , 2011, 43, 246-252.	9.4	1,201
715	To what extent are genetics clinically useful?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, S8-S14.	1.0	4
716	Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for <i>IL2</i> , <i>REL</i> , and <i>CARD9</i> . <i>Hepatology</i> , 2011, 53, 1977-1985.	3.6	110
717	Seroreactivity against glycolytic enzymes in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 557-564.	0.9	24
718	Genetic variation in the autophagy gene <i>ULK1</i> and risk of Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1392-1397.	0.9	137
719	Identification of a novel autoantigen in inflammatory bowel disease by protein microarray. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1291-1300.	0.9	33
720	Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1846-1854.	0.9	161

#	ARTICLE	IF	CITATIONS
721	Management of acute severe ulcerative colitis. <i>Gut</i> , 2011, 60, 130-133.	6.1	75
722	Immune reactivity to $\alpha$ -tubulin isotype 5 and vesicular integral-membrane protein 36 in patients with autoimmune gastrointestinal disorders. <i>Gut</i> , 2011, 60, 1601-1602.	6.1	12
723	The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. <i>Gut</i> , 2011, 60, 1068-1075.	6.1	128
724	Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use. <i>Rheumatology</i> , 2011, 50, 1955-1968.	0.9	111
725	Tolerability of Shortened Infliximab Infusion Times in Patients With Inflammatory Bowel Diseases: A Single-Center Cohort Study. <i>American Journal of Gastroenterology</i> , 2011, 106, 778-785.	0.2	32
726	Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. <i>Gut</i> , 2011, 60, 631-637.	6.1	871
727	Genetic Evidence Supporting the Association of Protease and Protease Inhibitor Genes with Inflammatory Bowel Disease: A Systematic Review. <i>PLoS ONE</i> , 2011, 6, e24106.	1.1	29
728	Early Serum Infliximab Trough Level, Clinical Disease Activity and CRP as Markers of Sustained Benefit of Infliximab Treatment in Crohn's Disease: A Post-hoc Analysis of the ACCENT1 Trial. <i>American Journal of Gastroenterology</i> , 2011, 106, S462-S463.	0.2	10
729	Mucosal Healing and anti TNFs in IBD. <i>Current Drug Targets</i> , 2010, 11, 227-233.	1.0	50
730	Likelihood ratio for Crohn's disease as a function of Anti-Saccharomyces cerevisiae antibody concentration. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 5-6.	0.9	3
731	Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 58-67.	0.9	34
732	Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: A Belgian case series. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 243-249.	0.9	104
733	Transmission Ratio Distortion of DLG5 R30Q: Evidence for Prenatal Selection?. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 910-911.	0.9	1
734	Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1299-1310.	0.9	90
735	Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 2090-2098.	0.9	151
736	The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 92-101.	1.9	108
737	Impact of lipoteichoic acid modification on the performance of the probiotic <i>Lactobacillus rhamnosus</i> GG in experimental colitis. <i>Clinical and Experimental Immunology</i> , 2010, 162, 306-314.	1.1	92
738	Genome-wide association study for ulcerative colitis identifies risk loci at 7q22 and 22q13 (IL17REL). <i>Nature Genetics</i> , 2010, 42, 292-294.	9.4	177

#	ARTICLE	IF	CITATIONS
739	Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. <i>Nature Genetics</i> , 2010, 42, 1118-1125.	9.4	2,284
740	Mutational Characterization of the Bile Acid Receptor TGR5 in Primary Sclerosing Cholangitis. <i>PLoS ONE</i> , 2010, 5, e12403.	1.1	106
741	Predicting the response to infliximab from trough serum levels. <i>Gut</i> , 2010, 59, 7-8.	6.1	33
742	Long-term outcome of endoscopic dilatation in patients with Crohn's disease is not affected by disease activity or medical therapy. <i>Gut</i> , 2010, 59, 320-324.	6.1	154
743	Evidence that glioma-associated oncogene homolog 1 is not a universal risk gene for inflammatory bowel disease in Caucasians. <i>Genes and Immunity</i> , 2010, 11, 509-514.	2.2	3
744	Genomic Copy Number Determines Functional Expression of Î²-Defensin 2 in Airway Epithelial Cells and Associates with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 163-169.	2.5	37
745	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 63-101.	0.6	695
746	Infliximab administered with shortened infusion times in a specialized IBD infusion unit: A prospective cohort study. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 329-333.	0.6	30
747	Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 355-366.	0.6	284
748	Rectal non-Hodgkin's lymphoma in an infliximab treated patient with ulcerative colitis and primary sclerosing cholangitis. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 683-686.	0.6	11
749	European evidenced-based consensus on reproduction in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 493-510.	0.6	140
750	S31 Mucosal healing in Crohn's disease is associated with high infliximab trough levels. <i>Journal of Crohn S and Colitis Supplements</i> , 2010, 4, 30-31.	0.0	3
751	Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease. <i>Gastroenterology</i> , 2010, 138, 463-468.	0.6	738
752	Genome-Wide Association Analysis in Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2010, 138, 1102-1111.	0.6	325
753	Postinfectious Irritable Bowel Syndrome: A Genetic Link Identified?. <i>Gastroenterology</i> , 2010, 138, 1246-1249.	0.6	2
754	Correlation Between the Crohn's Disease Activity and Harveyâ€Bradshaw Indices in Assessing Crohn's Disease Severity. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 357-363.	2.4	336
755	Serum S100A12 as a new marker for inflammatory bowel disease and its relationship with disease activity. <i>Gut</i> , 2010, 59, 1728.2-1729.	6.1	10
756	The potential for disease modification in Crohn's disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 79-85.	8.2	80

#	ARTICLE	IF	CITATIONS
757	Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 688-695.e2.	2.4	142
758	Molecular Reclassification of Crohn's Disease by Cluster Analysis of Genetic Variants. <i>PLoS ONE</i> , 2010, 5, e12952.	1.1	27
759	Vaccination and infection prevention in inflammatory bowel disease. <i>F1000 Medicine Reports</i> , 2010, 2, 80.	2.9	5
760	Role of genetics in prediction of disease course and response to therapy. <i>World Journal of Gastroenterology</i> , 2010, 16, 2609.	1.4	39
761	Compassionate Use of Certolizumab Pegol in Patients with Crohn's Disease Who Have Failed Previous TNF Inhibitor Therapies. <i>American Journal of Gastroenterology</i> , 2010, 105, S416.	0.2	0
762	Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. <i>Gut</i> , 2009, 58, 492-500.	6.1	479
763	Genetic analysis to predict prognosis at the onset of Crohn's disease: not yet ready for prime time?. <i>Gut</i> , 2009, 58, 323-324.	6.1	3
764	Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. <i>Gut</i> , 2009, 58, 501-508.	6.1	391
765	Accurate determination of copy number variations (CNVs): Application to the $\beta$ - and $\beta$ -defensin CNVs. <i>Journal of Immunological Methods</i> , 2009, 344, 35-44.	0.6	13
766	Infliximab therapy for patients with inflammatory bowel disease: 10years on. <i>European Journal of Pharmacology</i> , 2009, 623, S17-S25.	1.7	20
767	Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1062-1070.	0.9	225
768	Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1295-1301.	0.9	584
769	Outcome of surgery for rectovaginal fistula due to Crohn's disease. <i>British Journal of Surgery</i> , 2009, 96, 1190-1195.	0.1	47
770	Clustering of (auto)immune diseases with early-onset and complicated inflammatory bowel disease. <i>European Journal of Pediatrics</i> , 2009, 168, 575-583.	1.3	8
771	Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and crohn's disease). <i>Current Gastroenterology Reports</i> , 2009, 11, 504-508.	1.1	9
772	The IL-10R1 S138G loss-of-function allele and ulcerative colitis. <i>Genes and Immunity</i> , 2009, 10, 84-92.	2.2	29
773	Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. <i>Nature Genetics</i> , 2009, 41, 71-76.	9.4	448
774	Common variants at five new loci associated with early-onset inflammatory bowel disease. <i>Nature Genetics</i> , 2009, 41, 1335-1340.	9.4	459



#	ARTICLE	IF	CITATIONS
775	Serum sickness, encephalitis and other complications of anti-cytokine therapy. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2009, 23, 101-112.	1.0	45
776	Cystic fibrosis transmembrane conductance regulator gene polymorphisms in patients with primary sclerosing cholangitis. Journal of Hepatology, 2009, 50, 150-157.	1.8	43
777	Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease. Journal of Crohn's and Colitis, 2009, 3, 4-7.	0.6	114
778	Reply to Dr. Caprilli et al.'s letter. Journal of Crohn's and Colitis, 2009, 3, 45.	0.6	0
779	Electronic Clinical Challenges and Images in GI. Gastroenterology, 2009, 136, e5-e6.	0.6	4
780	Biological Therapies for Inflammatory Bowel Diseases. Gastroenterology, 2009, 136, 1182-1197.	0.6	340
781	Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease. Gastroenterology, 2009, 137, 1628-1640.	0.6	460
782	Confirmation of Multiple Crohn's Disease Susceptibility Loci in a Large Dutch-Belgian Cohort. American Journal of Gastroenterology, 2009, 104, 630-638.	0.2	111
783	Candida albicans Colonization and ASCA in Familial Crohn's Disease. American Journal of Gastroenterology, 2009, 104, 1745-1753.	0.2	172
784	Mesalamine Once Daily Is More Effective Than Twice Daily in Patients With Quiescent Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2009, 7, 762-769.	2.4	130
785	Genetic Risk Profiling and Prediction of Disease Course in Crohn's Disease Patients. Clinical Gastroenterology and Hepatology, 2009, 7, 972-980.e2.	2.4	138
786	Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut, 2009, 58, 1612-1619.	6.1	346
787	IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab. Pharmacogenetics and Genomics, 2009, 19, 383-387.	0.7	72
788	Polymorphisms in innate immunity genes predispose to bacteremia and death in the medical intensive care unit*. Critical Care Medicine, 2009, 37, 192-e3.	0.4	130
789	Immunosuppression in inflammatory bowel disease: traditional, biological or both?. Current Opinion in Gastroenterology, 2009, 25, 323-328.	1.0	11
790	Genetic Variants of Wnt Transcription Factor TCF-4 (TCF7L2) Putative Promoter Region Are Associated with Small Intestinal Crohn's Disease. PLoS ONE, 2009, 4, e4496.	1.1	125
791	Genetic Variation in the Familial Mediterranean Fever Gene (MEFV) and Risk for Crohn's Disease and Ulcerative Colitis. PLoS ONE, 2009, 4, e7154.	1.1	53
792	Mucosal Gene Expression of Antimicrobial Peptides in Inflammatory Bowel Disease Before and After First Infliximab Treatment. PLoS ONE, 2009, 4, e7984.	1.1	237

#	ARTICLE	IF	CITATIONS
793	Efficacy of Certolizumab Pegol in Crohn's Disease Patients with Secondary Failure to Infliximab Is Not Affected by Concomitant Medications. American Journal of Gastroenterology, 2009, 104, S451-S452.	0.2	1
794	Prediction of treatment success " will there be genetic or serological markers?. , 2009, , 86-92.		0
795	Confirmation of Multiple Crohn's Disease Susceptibility Loci in a Large Dutch-Belgian Cohort. American Journal of Gastroenterology, 2009, 104, 630-638.	0.2	23
796	Regain of Response and Remission by Dose Adjustment in Patients with Crohn's Disease Who Responded to Certolizumab Pegol: Results from the WELCOME Study. American Journal of Gastroenterology, 2009, 104, S450-S451.	0.2	0
797	Efficacy of Certolizumab Pegol is Not Affected by Baseline Anti-infliximab Antibody Status in Patients with Crohn's Disease with Secondary Infliximab Failure. American Journal of Gastroenterology, 2009, 104, S452.	0.2	0
798	Coamplification of Eukaryotic DNA with 16S rRNA Gene-Based PCR Primers: Possible Consequences for Population Fingerprinting of Complex Microbial Communities. Current Microbiology, 2008, 56, 553-557.	1.0	50
799	The Crohn's disease susceptibility gene DLG5 as a member of the CARD interaction network. Journal of Molecular Medicine, 2008, 86, 423-432.	1.7	20
800	Optimizing treatment of inflammatory bowel diseases with biologic agents. Current Gastroenterology Reports, 2008, 10, 591-596.	1.1	19
801	Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Inflammatory Bowel Diseases, 2008, 14, 20-28.	0.9	159
802	Transcriptomic analysis of intestinal fibrosis-associated gene expression in response to medical therapy in Crohn's disease. Inflammatory Bowel Diseases, 2008, 14, 1197-1204.	0.9	37
803	Should family members of IBD patients be screened for CARD15/NOD2 mutations?. Inflammatory Bowel Diseases, 2008, 14, S190-S191.	0.9	5
804	Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nature Genetics, 2008, 40, 955-962.	9.4	2,422
805	Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nature Genetics, 2008, 40, 1319-1323.	9.4	534
806	494 Efficacy and Safety of Certolizumab Pegol in Patients with Active Crohn's Disease Who Previously Lost Response or Were Intolerant to Infliximab: Open-Label Induction Preliminary Results of the Welcome Study. Gastroenterology, 2008, 134, A-67-A-68.	0.6	12
807	Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial. Gastroenterology, 2008, 134, 1861-1868.	0.6	477
808	Therapy of Metronidazole With Azathioprine to Prevent Postoperative Recurrence of Crohn's Disease: A Controlled Randomized Trial. Gastroenterology, 2008, 135, 1123-1129.	0.6	281
809	Serological markers are associated with disease course in ulcerative colitis. A study in an unselected population-based cohort followed for 10 years. Journal of Crohn's and Colitis, 2008, 2, 114-122.	0.6	32
810	Development of pouchitis following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis: A role for serological markers and microbial pattern recognition receptor genes. Journal of Crohn's and Colitis, 2008, 2, 142-151.	0.6	35

#	ARTICLE	IF	CITATIONS
811	European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. Journal of Crohn's and Colitis, 2008, 2, 1-23.	0.6	470
812	Long-term outcome after infliximab for refractory ulcerative colitis. Journal of Crohn's and Colitis, 2008, 2, 219-225.	0.6	190
813	Management of loss of response to anti-TNF drugs: Change the dose or change the drug?. Journal of Crohn's and Colitis, 2008, 2, 348-351.	0.6	11
814	Predicting relapse in Crohn's disease: a biopsychosocial model. Gut, 2008, 57, 1386-1392.	6.1	198
815	Serological markers in inflammatory bowel disease. Immuno-Analyse Et Biologie Specialisee, 2008, 23, 358-367.	0.0	4
816	Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet, The, 2008, 371, 660-667.	6.3	1,135
817	(Auto)Antibodies in Inflammatory Bowel Diseases. Gastroenterology Clinics of North America, 2008, 37, 429-438.	1.0	18
818	Anti-â€œenolase Antibodies in Patients with Inflammatory Bowel Disease. Clinical Chemistry, 2008, 54, 534-541.	1.5	41
819	Detection of Antisynthetic Mannoside Antibodies (AÎ£MA) Reveals Heterogeneity in the ASCA Response of Crohn's Disease Patients and Contributes to Differential Diagnosis, Stratification, and Prediction. American Journal of Gastroenterology, 2008, 103, 949-957.	0.2	25
820	JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?. Gut, 2008, 57, 1393-1397.	6.1	55
821	Should family members of IBD patients be screened for CARD15/NOD2 mutations?. Inflammatory Bowel Diseases, 2008, 14, S190-S191.	0.9	1
822	The Role of Genetics in Inflammatory Bowel Disease. Current Drug Targets, 2008, 9, 361-368.	1.0	28
823	Certolizumab Pegol Is Efficacious in Crohn's Disease Patients Who Have Failed Infliximab Regardless of Concomitant Therapy or Reason for Failure. American Journal of Gastroenterology, 2008, 103, S430-S431.	0.2	2
824	Treatment of severe steroid refractory ulcerative colitis. World Journal of Gastroenterology, 2008, 14, 5508.	1.4	45
825	Infliximab: the evidence for its place in therapy in ulcerative colitis. Core Evidence, 2008, 2, 151-61.	4.7	1
826	Infliximab for pediatric Crohn's disease. Drugs of Today, 2008, 44, 615.	0.7	0
827	Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?. Gut, 2007, 56, 453-455.	6.1	275
828	Role of biomarkers in the diagnosis of inflammatory bowel disease. Expert Opinion on Medical Diagnostics, 2007, 1, 481-488.	1.6	4

#	ARTICLE	IF	CITATIONS
829	Treatment inferred disease severity in Crohn's disease: Evidence for a European gradient of disease course. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 333-344.	0.6	22
830	The RANTES -28 g polymorphism is associated with primary sclerosing cholangitis. <i>Gut</i> , 2007, 56, 891-892.	6.1	4
831	Gender-stratified analysis of DLG5 R30Q in 4707 patients with Crohn disease and 4973 controls from 12 Caucasian cohorts. <i>Journal of Medical Genetics</i> , 2007, 45, 36-42.	1.5	47
832	Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. <i>Gut</i> , 2007, 56, 1536-1542.	6.1	91
833	An insertion deletion polymorphism in the Interferon Regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. <i>Human Molecular Genetics</i> , 2007, 16, 3008-3016.	1.4	163
834	New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. <i>Gut</i> , 2007, 56, 1394-1403.	6.1	267
835	Dysplasia and Cancer in Inflammatory Bowel Disease 10 Years after Diagnosis: Results of a Population-Based European Collaborative Follow-Up Study. <i>Digestion</i> , 2007, 75, 113-121.	1.2	48
836	Familial Crohn's Disease in Belgium. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 583-590.	1.1	18
837	Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. <i>Gut</i> , 2007, 56, 1226-1231.	6.1	539
838	Prevalence of CARD15/NOD2 Mutations in Caucasian Healthy People. <i>American Journal of Gastroenterology</i> , 2007, 102, 1259-1267.	0.2	249
839	American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21-23, 2006. <i>Gastroenterology</i> , 2007, 133, 312-339.	0.6	197
840	007 LONG-TERM SAFETY OF INFLIXIMAB IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: A SINGLE CENTER COHORT STUDY. <i>Journal of Crohn S and Colitis Supplements</i> , 2007, 1, 3.	0.0	1
841	Effect of phenotype on health care costs in Crohn's disease: A European study using the Montreal classification. <i>Journal of Crohn's and Colitis</i> , 2007, 1, 87-96.	0.6	22
842	Intravenous iron therapy restores functional iron deficiency induced by infliximab. <i>Journal of Crohn's and Colitis</i> , 2007, 1, 97-105.	0.6	21
843	Perianal Crohn's disease: Classification and clinical evaluation. <i>Digestive and Liver Disease</i> , 2007, 39, 959-962.	0.4	53
844	Novel Crohn Disease Locus Identified by Genome-Wide Association Maps to a Gene Desert on 5p13.1 and Modulates Expression of PTGER4. <i>PLoS Genetics</i> , 2007, 3, e58.	1.5	506
845	Predictive Model for the Outcome of Infliximab Therapy in Crohn's Disease Based on Apoptotic Pharmacogenetic Index and Clinical Predictors. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 372-379.	0.9	64
846	The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 24-32.	0.9	71

#	ARTICLE	IF	CITATIONS
847	Predictors of early response to infliximab in patients with ulcerative colitis. Inflammatory Bowel Diseases, 2007, 13, 123-128.	0.9	166
848	NOD2/CARD15 disease associations other than Crohn's disease. Inflammatory Bowel Diseases, 2007, 13, 235-241.	0.9	52
849	Contribution of genetic and environmental factors in the pathogenesis of Crohn's disease in a large family with multiple cases. Inflammatory Bowel Diseases, 2007, 13, 580-584.	0.9	24
850	Endoscopic therapy of strictures in Crohn's disease. Inflammatory Bowel Diseases, 2007, 13, 356-358.	0.9	30
851	Role of ASCA and the NOD2/CARD15 mutation Gly908Arg in predicting increased surgical costs in Crohn's disease patients: A project of the European Collaborative Study Group on Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2007, 13, 874-881.	0.9	22
852	Restoration of soluble CD146 in patients with Crohn's disease treated with the TNF-Î± antagonist infliximab. Inflammatory Bowel Diseases, 2007, 13, 1315-1317.	0.9	8
853	Toll-like receptor 2 and Toll-like receptor 4 polymorphisms in invasive pneumococcal disease. Microbes and Infection, 2007, 9, 15-20.	1.0	40
854	The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes and Immunity, 2007, 8, 387-397.	2.2	129
855	Clinical and genetic factors associated with sacroiliitis in Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2007, 23, 070827235605003-???	1.4	54
856	Search for evidence of recurring or persistent viruses in Crohn's disease. Apmis, 2007, 115, 962-968.	0.9	22
857	L'infliximab dans le traitement prolongé de la maladie de Crohn non fistulisante. Acta Endoscopica, 2007, 37, 271-283.	0.0	0
858	Use of serology and genetics to differentiate inflammatory bowel disease phenotypes. , 2007, , 48-54.		0
859	Compassionate Use of Certolizumab Pegol in Patients with Crohn's Disease for Whom Treatment with One or Two Anti-TNFs Failed. American Journal of Gastroenterology, 2007, 102, S484.	0.2	0
860	Adalimumab in Crohn's disease. Biologics: Targets and Therapy, 2007, 1, 355-65.	3.0	4
861	Serologic Markers in the Diagnosis and Management of IBD. Gastroenterology and Hepatology, 2007, 3, 424-6.	0.2	1
862	The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut, 2006, 55, 749-753.	6.1	2,362
863	Incidence of Colectomy During Long-term Follow-up After Cyclosporine-Induced Remission of Severe Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2006, 4, 760-765.	2.4	284
864	Focus on Mechanisms of Inflammation in Inflammatory Bowel Disease Sites of Inhibition: Current and Future Therapies. Gastroenterology Clinics of North America, 2006, 35, 743-756.	1.0	17

#	ARTICLE	IF	CITATIONS
865	The Value of Myenteric Plexitis to Predict Early Postoperative Crohn's Disease Recurrence. <i>Gastroenterology</i> , 2006, 130, 1595-1606.	0.6	150
866	Cost Analysis and Cost Determinants in a European Inflammatory Bowel Disease Inception Cohort With 10 Years of Follow-up Evaluation. <i>Gastroenterology</i> , 2006, 131, 719-728.	0.6	213
867	Disease outcome of inflammatory bowel disease patients: General outline of a Europe-wide population-based 10-year clinical follow-up study. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 46-54.	0.6	71
868	NOD2/CARD15 mutations in Croatian patients with Crohn's disease: prevalence and genotype-phenotype relationship. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 895-899.	0.8	20
869	The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 727-734.	0.7	35
870	New and Old Serological Markers in IBD. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2006, 43, S21.	0.9	0
871	Immunogenicity. <i>Inflammatory Bowel Diseases</i> , 2006, 12, S13-S14.	0.9	0
872	Myenteric Plexitis in Unaffected Ileal Resection Margins Predicts Severe and Early Postoperative Crohn's Disease Recurrence. <i>Inflammatory Bowel Diseases</i> , 2006, 12, S29.	0.9	0
873	Safety issues with biological therapies for inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 2006, 22, 370-376.	1.0	25
874	No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 37-42.	0.7	40
875	Optimizing Anti-TNF- $\alpha$ Therapy in IBD. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2006, 43, S35-S36.	0.9	0
876	DLG5 R30Q Is Not Associated With IBD in Hungarian IBD Patients but Predicts Clinical Response to Steroids in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 362-368.	0.9	25
877	Lymphotoxin alpha gene in Crohn's disease patients: absence of implication in the response to infliximab in a large cohort study. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 369-373.	0.7	20
878	Validation of 16S rDNA sequencing in microdissected bowel biopsies from Crohn's disease patients to assess bacterial flora diversity. <i>Journal of Pathology</i> , 2006, 209, 532-539.	2.1	31
879	Review article: infliximab therapy for inflammatory bowel disease - seven years on. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 451-463.	1.9	221
880	Review article: genetic susceptibility and application of genetic testing in clinical management of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 2-10.	1.9	47
881	Review article: altering the natural history of Crohn's disease ? evidence for and against current therapies. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 25, 061016063002002-???	1.9	101
882	Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 1-8.	0.9	249



#	ARTICLE	IF	CITATIONS
883	CC-Type chemokine receptor 5-Î”32 mutation protects against primary sclerosing cholangitis. Inflammatory Bowel Diseases, 2006, 12, 272-277.	0.9	25
884	Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn’s disease. Inflammatory Bowel Diseases, 2006, 12, 199-204.	0.9	72
885	The role of vascular endothelial growth factor (VEGF) in inflammatory bowel disease. Inflammatory Bowel Diseases, 2006, 12, 870-878.	0.9	46
886	The changing face of treatment for Crohn’s disease. British Journal of Surgery, 2006, 93, 385-386.	0.1	5
887	Emerging Biological Treatments in Inflammatory Bowel Diseases. Digestive Diseases, 2006, 24, 131-136.	0.8	12
888	Mannan binding lectin (MBL) gene polymorphisms are not associated with anti-Saccharomyces cerevisiae (ASCA) in patients with Crohn’s disease. Gut, 2006, 55, 746-746.	6.1	17
889	Crohn’s disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut, 2006, 55, 510-518.	6.1	113
890	Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut, 2006, 55, 426-431.	6.1	745
891	Does Pregnancy Change the Disease Course? A Study in a European Cohort of Patients with Inflammatory Bowel Disease. American Journal of Gastroenterology, 2006, 101, 1539-1545.	0.2	163
892	European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. Gut, 2006, 55, i1-i15.	6.1	472
893	Pharmacogenetics in inflammatory bowel disease. World Journal of Gastroenterology, 2006, 12, 3657.	1.4	45
894	Biologics: old and new ones. , 2006, , 71-77.		0
895	Medical treatment of inflammatory bowel diseases. Current Opinion in Internal Medicine, 2005, 4, 457-461.	1.5	2
896	The impact of uridine diphosphateâ€“glucuronosyltransferase 1A9 () gene promoter region single-nucleotide polymorphisms and on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clinical Pharmacology and Therapeutics, 2005, 78, 351-361.	2.3	171
897	The impact of major depressive disorder on the short- and long-term outcome of Crohn’s disease treatment with infliximab. Alimentary Pharmacology and Therapeutics, 2005, 22, 101-110.	1.9	209
898	Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn’s disease. Alimentary Pharmacology and Therapeutics, 2005, 22, 613-626.	1.9	179
899	Current status of genetics research in inflammatory bowel disease. Genes and Immunity, 2005, 6, 637-645.	2.2	96
900	Environmental Factors in Familial Crohn’s Disease in Belgium. Inflammatory Bowel Diseases, 2005, 11, 360-365.	0.9	69

#	ARTICLE	IF	CITATIONS
901	Crohn's Disease and Month of Birth. Inflammatory Bowel Diseases, 2005, 11, 597-599.	0.9	32
902	Hyperresponsiveness of the Mucosal Barrier in Crohn's Disease Is Not Tumor Necrosis Factor-Dependent. Inflammatory Bowel Diseases, 2005, 11, 667-673.	0.9	31
903	Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Canadian Journal of Gastroenterology & Hepatology, 2005, 19, 5A-36A.	1.8	2,711
904	Epithelioid granulomas, pattern recognition receptors, and phenotypes of Crohn's disease. Gut, 2005, 54, 223-227.	6.1	81
905	Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut, 2005, 55, 1124-1130.	6.1	207
906	Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease. New England Journal of Medicine, 2005, 353, 362-368.	13.9	1,015
907	Tumor Necrosis Factor Receptor Gene Polymorphisms in Crohn's Disease: Association with Clinical Phenotypes. American Journal of Gastroenterology, 2005, 100, 1126-1133.	0.2	67
908	Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: A randomized, double-blind, placebo-controlled trial. Gastroenterology, 2005, 128, 856-861.	0.6	401
909	Functional IL12B Variant Interacts With Response to Infliximab Treatment in Crohn's Disease. Gastroenterology, 2005, 129, 1104.	0.6	0
910	Association of Organic Cation Transporter Risk Haplotype With Perianal Penetrating Crohn's Disease but Not With Susceptibility to IBD. Gastroenterology, 2005, 129, 1845-1853.	0.6	136
911	The use of immunosuppressive drugs in IBD: RAND or random choice?. Digestive and Liver Disease, 2005, 37, 391-393.	0.4	0
912	The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 580-586.	1.7	115
913	Medical treatment of inflammatory bowel diseases. Current Opinion in Gastroenterology, 2005, 21, 443-7.	1.0	37
914	Genome wide scan in a Flemish inflammatory bowel disease population: support for the IBD4 locus, population heterogeneity, and epistasis. Gut, 2004, 53, 980-986.	6.1	73
915	Interassay and Interobserver Variability in the Detection of Anti-neutrophil Cytoplasmic Antibodies in Patients with Ulcerative Colitis. Clinical Chemistry, 2004, 50, 1422-1425.	1.5	32
916	Diagnostic Accuracy of Ten Second-Generation (Human) Tissue Transglutaminase Antibody Assays in Celiac Disease. Clinical Chemistry, 2004, 50, 2125-2135.	1.5	103
917	Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2004, 19, 511-519.	1.9	198
918	The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Alimentary Pharmacology and Therapeutics, 2004, 19, 749-754.	1.9	212

#	ARTICLE	IF	CITATIONS
919	Tumour necrosis factor-Î± receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 303-310.	1.9	138
920	Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 607-614.	1.9	74
921	Novel Biological Strategies in Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2004, 10, S44-S51.	0.9	5
922	Long-term Outcome of Treatment with Intravenous Cyclosporin in Patients With Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2004, 10, 73-78.	0.9	208
923	C-Reactive Protein as a Marker for Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2004, 10, 661-665.	0.9	400
924	Pancreatic Autoantibodies in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2004, 10, 771-777.	0.9	54
925	NOD2/CARD15: relevance in clinical practice. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2004, 18, 569-575.	1.0	36
926	Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. <i>Gut</i> , 2004, 53, 987-992.	6.1	515
927	Antibody responses in Crohn's disease. <i>Gastroenterology</i> , 2004, 126, 601-604.	0.6	19
928	Optimizing anti-TNF treatment in inflammatory bowel disease. <i>Gastroenterology</i> , 2004, 126, 1593-1610.	0.6	463
929	Transmission of CARD15 (NOD2) Variants Within Families of Patients with Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2004, 99, 299-305.	0.2	63
930	The role and importance of endoscopic mucosal healing in Crohn's disease. <i>Techniques in Gastrointestinal Endoscopy</i> , 2004, 6, 138-143.	0.3	5
931	MANAGEMENT OF ULCERATIVE COLITIS AND CROHN'S DISEASE. <i>Acta Clinica Belgica</i> , 2004, 59, 304-314.	0.5	27
932	Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease. <i>New England Journal of Medicine</i> , 2003, 348, 601-608.	13.9	1,942
933	Small bowel review: Normal physiology, part 1. <i>Digestive Diseases and Sciences</i> , 2003, 48, 1546-1564.	1.1	22
934	Small bowel review: Normal physiology, part 2. <i>Digestive Diseases and Sciences</i> , 2003, 48, 1565-1581.	1.1	15
935	REVIEW: Introduction to Small Bowel Review. <i>Digestive Diseases and Sciences</i> , 2003, 48, 1545-1545.	1.1	0
936	Small bowel review: Diseases of the small intestine. <i>Digestive Diseases and Sciences</i> , 2003, 48, 1582-1599.	1.1	4

#	ARTICLE	IF	CITATIONS
937	VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. <i>Nature Genetics</i> , 2003, 34, 383-394.	9.4	794
938	No association between month of birth and Crohn's disease. <i>Gastroenterology</i> , 2003, 124, A215.	0.6	0
939	Impact of infliximab on weight regulation and lipid metabolism: Immunoneutralization of TNF $\alpha$ induces leptinemia in Crohn's disease. <i>Gastroenterology</i> , 2003, 124, A334.	0.6	0
940	Panel of serologic antibodies in patients with indeterminate colitis. <i>Gastroenterology</i> , 2003, 124, A323.	0.6	2
941	Autoimmunity associated with anti-tumor necrosis factor $\alpha$ treatment in Crohn's disease: a prospective cohort study. <i>Gastroenterology</i> , 2003, 125, 32-39.	0.6	305
942	Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gert Van Assche, Severine Vermeire, Geert D'Haens, and Paul Rutgeerts have been instrumental in the design of the study, trial management, data analysis, and writing the paper. Maja Noman had a major contribution in the clinical ambulatory follow-up of the patients in the trial. Martin Hiele followed cyclosporine levels and adjusted drug doses of patients in the trial and provided statistics. <i>Gastroenterology</i> , 2003, 125, 1025-1031.	0.6	433
943	A polymorphism in IgG Fc receptor gene FCGR3A is associated with biological response to infliximab in Crohn disease. <i>Gastroenterology</i> , 2003, 124, A2.	0.6	2
944	Anti-saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease: Stability over time and correlation with clinical characteristics. <i>Gastroenterology</i> , 2003, 124, A194.	0.6	0
945	Crohn disease is associated with the Toll-like receptor (TLR)-4 polymorphism Asp299Gly: further evidence for a deficient bacterial recognition in the triggering of the disease. <i>Gastroenterology</i> , 2003, 124, A371.	0.6	0
946	Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. <i>American Journal of Gastroenterology</i> , 2002, 97, 1458-1462.	0.2	136
947	The value of serologic markers in indeterminate colitis: A prospective follow-up study. <i>Gastroenterology</i> , 2002, 122, 1242-1247.	0.6	340
948	NOD2/CARD15 does not influence response to infliximab in Crohn's disease. <i>Gastroenterology</i> , 2002, 123, 106-111.	0.6	198
949	Inflammatory Bowel Disease A Positive Response to Infliximab in Crohn Disease: Association with a Higher Systemic Inflammation Before Treatment But Not With -308 TNF Gene Polymorphism. <i>Scandinavian Journal of Gastroenterology</i> , 2002, 37, 818-824.	0.6	237
950	CARD15 Genetic Variation in a Quebec Population: Prevalence, Genotype-Phenotype Relationship, and Haplotype Structure. <i>American Journal of Human Genetics</i> , 2002, 71, 74-83.	2.6	253
951	Interleukin-1 receptor antagonist VNTR-polymorphism in inflammatory bowel disease. <i>Genes and Immunity</i> , 2002, 3, 400-406.	2.2	27
952	Inflammatory Bowel Disease A Positive Response to Infliximab in Crohn Disease: Association with a Higher Systemic Inflammation Before Treatment But Not With -308 TNF Gene Polymorphism. <i>Scandinavian Journal of Gastroenterology</i> , 2002, 37, 818-824.	0.6	68
953	Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. <i>American Journal of Gastroenterology</i> , 2002, 97, 2357-2363.	0.2	203
954	A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. <i>Scandinavian Journal of Gastroenterology</i> , 2002, 37, 818-24.	0.6	68

#	ARTICLE	IF	CITATIONS
955	Evidence for inflammatory bowel disease of a susceptibility locus on the X chromosome. <i>Gastroenterology</i> , 2001, 120, 834-840.	0.6	46
956	Comparative study of ASCA (Anti-��Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. <i>Gastroenterology</i> , 2001, 120, 827-833.	0.6	136
957	Inflammatory bowel disease in spouses and their offspring. <i>Gastroenterology</i> , 2001, 120, 816-819.	0.6	109
958	Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. <i>Gastroenterology</i> , 2001, 120, 1323-1329.	0.6	394
959	MRI imaging of the effects of infliximab in perianal fistulizing Crohn's disease. <i>Gastroenterology</i> , 2001, 120, A68.	0.6	8
960	Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2001, 96, 730-734.	0.2	350
961	Analysis of the CC chemokine receptor 5 (CCR5) delta-32 polymorphism in inflammatory bowel disease. <i>Human Genetics</i> , 2001, 108, 190-193.	1.8	35
962	Anti-Saccharomyces Cerevisiae Antibodies (ASCA), Phenotypes of IBD, and Intestinal Permeability: A Study in IBD Families. <i>Inflammatory Bowel Diseases</i> , 2001, 7, 8-15.	0.9	156
963	Mannan-binding lectin (MBL) gene polymorphisms in ulcerative colitis and Crohn��s disease. <i>Genes and Immunity</i> , 2001, 2, 323-328.	2.2	52
964	Infliximab (Remicade) treatment in Crohn's disease and antinuclear antibody (ANA) formation. <i>Gastroenterology</i> , 2001, 120, A69-A69.	0.6	6
965	Exclusion of Linkage of Crohn��s Disease to Previously Reported Regions on Chromosomes 12, 7, and 3 in the Belgian Population Indicates Genetic Heterogeneity. <i>Inflammatory Bowel Diseases</i> , 2000, 6, 165-170.	0.9	24
966	Familial and Sporadic Inflammatory Bowel Disease: Different Entities?. <i>Inflammatory Bowel Diseases</i> , 2000, 6, 314-320.	0.9	26
967	Familial and sporadic inflammatory bowel disease: Different entities?. <i>Inflammatory Bowel Diseases</i> , 2000, 6, 314-320.	0.9	34
968	Serological diagnosis of inflammatory bowel disease. <i>Lancet, The</i> , 2000, 356, 2117-2118.	6.3	20
969	CC chemokine receptor 5 (CCR-5) and serological markers ASCA and pANCA in inflammatory bowel disease (IBD). <i>Gastroenterology</i> , 2000, 118, A1375.	0.6	0
970	Surgery is associated with fluctuations in ASCA levels suggesting antigenic stimulation. <i>Gastroenterology</i> , 2000, 118, A1369.	0.6	1
971	Two and four mg/kg/day of intravenous cyclosporine are equally effective in severe attacks of ulcerative colitis. <i>Gastroenterology</i> , 2000, 118, A786.	0.6	3
972	Are anti-saccharomyces cerevisiae antibodies (ASCA) and perinuclear antineutrophil cytoplasmic antibodies (PANCA) useful in indeterminate colitis? A prospective follow-up study. <i>Gastroenterology</i> , 2000, 118, A886.	0.6	5

#	ARTICLE	IF	CITATIONS
973	Response to anti-tnf treatment is associated with the TNFA-308*1 allele. Gastroenterology, 2000, 118, A654.	0.6	8
974	Diagnostic value of ASCA (anti-saccharomyces cerevisiae antibodies) and pANCA (perinuclear) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 707 A105.	0.6	2
975	ASCA and pANCA in a new Belgian IBD dataset. Gastroenterology, 2000, 118, A107.	0.6	0
976	Chemokine receptor CCR5 Î”32 gene polymorphism in Crohn's disease and ulcerative colitis. Gastroenterology, 2000, 118, A114.	0.6	2
977	Clinical value of the detection of antibodies in the serum for diagnosis and treatment of inflammatory bowel disease. Gastroenterology, 1998, 115, 1006-1009.	0.6	56
978	No evidence for linkage on chromosomes 16-12-7 and 3 in the belgian population may reflect genetic heterogeneity of inflammatory bowel disease. Gastroenterology, 1998, 114, A1109.	0.6	3
979	Genetics of inflammatory bowel disease: Contribution of the X chromosome. Gastroenterology, 1998, 114, A1077.	0.6	0
980	Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology, 1997, 113, 802-807.	0.6	243
981	Cyclosporine monotherapy is effective in the treatment of severe ulcerative colitis. Inflammatory Bowel Diseases, 1996, 2, 253-254.	0.9	2
982	Cyclosporine monotherapy is effective in the treatment of severe ulcerative colitis. Inflammatory Bowel Diseases, 1996, 2, 253-4.	0.9	0
983	Dealing With Infusion Reactions. , 0, , 67-69.		0
984	Anti-MAdCAM antibody for induction of remission in ulcerative colitis. The Cochrane Library, 0, , .	1.5	0
985	Endoscopy in Inflammatory Bowel Diseases. , 0, , 646-658.		0